Top

Gabriela Rondon, M.D.

Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine

About Dr. Gabriela Rondon

Dr. Gabriela Rondón is an Professor in the Department of Stem Cell Transplantation and Cellular Therapy at the M. D. Anderson Cancer Center in Houston, Texas. She completed her Post Doctoral fellowship training here at the University of Texas M. D. Anderson, and began her tenure in 1995. She has made important clinical observations resulting in the description of a “graft versus leukemia effect in CLL” as well as defining the role of different strategies for treatment of graft failure that has led to our current “standards of practice” within the department. She also developed our current guidelines for adverse event reporting in the context of high dose therapy and stem cell transplantation. These guidelines led to a more homogeneous and relevant reporting of adverse outcomes in these settings of high dose therapy and stem cell transplantation. Dr. Rondón has been a close collaborator of Dr. Martin Korbling in his research related to the potential role of stem cell plasticity. In recent years she has instituted a prospective toxicity grading system by the protocol research staff for all SCTCT clinical trials, which has markedly improved the objectivity and responsibility of toxicity grading. As the Director of Protocol Research and Data Management. She has been actively involved in implementing strategies to assure successful protocol development and execution. She has also lead one of our most important obligations related to our data management activities with the Center for International Blood and Marrow Transplant Research (CIBMTR) and is an active member of hematology and oncology professional societies including American Association for Cancer Research, American Society of Hematology, and American Society for Blood and Marrow Transplantation.

Primary Appointment

Professor, Department of Stem Cell Transplantation - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1985	Universidad Central de Venezuela, Caracas, VE, Medicine, MedicoCirujano

Postgraduate Training

1992-1994	Post-Doctoral Fellow, Hematology (M. Andreeff), The University of Texas MD Anderson Cancer Center, Houston, Texas
1991-1992	Post-Doctoral Fellow, Pheresis and Bone Marrow Transplantation (J. Hester), The University of Texas MD Anderson Cancer Center, Houston, Texas
1986-1987	Post -Doctoral Fellow, Pharmacology & Cell Biophysics (J. Hartman), University of Cincinnati, Cincinnati, Ohio

Experience & Service

Faculty Academic Appointments

Associate Professor, Department of Stem Cell Transplantation - Research, The University of Texas, MD Anderson Cancer Center, Houston, TX, 2011 - 2019

Assistant Professor, Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX, 2003 - 2011

Instructor, Department of Stem Cell Transplantation - Research, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 1999 - 2003

Research Associate, Department of Stem Cell Transplantation - Research, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 1995 - 1999

Administrative Appointments/Responsibilities

Director of Data Management, Department of Stem Cell Transplantation - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present

Director, Protocol Research and Data Management, Department of Stem Cell Transplantation, University of Texas MD Anderson Cancer Center, Houston, TX, 2005 - 2020

Quality Assurance for Clinical Trials, Department of Stem Cell Transplantation - Research, University of Texas M.D. Anderson Cancer Center, Houston, TX, 2000 - 2005

Other Professional Positions

Research Faculty Appointment Panel (RFA Panel), MD Anderson Cancer Center, Houston, Texas, 2025 - Present

Member, ASTCT Guidelines Committee- Standardizing definitions of engraftment, rejection, and graft failure in allogeneic hematopoietic cell transplantation, Houston, TX, 2019 - 2021

Intramural Institutional Committee Activities

Member, Subcommittee for Faculty Achievement Awards for the 2024 Convocation, The University of Texas MD Anderson Cancer Center, 2024 - 2026

Vice Chair, Institutional Review Board V, The University of Texas MD Anderson Cancer Center, 2023 - Present

Vice Chair, Institutional Review Board III, The University of Texas MD Anderson Cancer Center, 2023 - Present

Member, Research Faculty Appointment (RFA) Panel, The University of Texas MD Anderson Cancer Center, 2020 - Present

Chair, Data Governance Sub-Committee, The University of Texas MD Anderson Cancer Center, 2014 - 2015

Member, HRPP Protocol Build Committee, The University of Texas MD Anderson Cancer Center, 2014 - 2015

Vice-Chair, Institutional Review Board l, The University of Texas MD Anderson Cancer Center, 2014 - 2016

Co-author with Dr. Ralph Freedman, Institutional Review Board Policy Reporting Adverse Events, The University of Texas MD Anderson Cancer Center, 2012

Vice Chair, Institutional Review Board V, The University of Texas MD Anderson Cancer Center, 2009 - 2013

Associate Member, Institutional Review Board V, The University of Texas MD Anderson Cancer Center, 2007 - 2023

Member, Institutional Review Board AD Hoc Policy Development for Reporting Adverse Events, The University of Texas MD Anderson Cancer Center, 2006

Associate Member, Institutional Review Board I, The University of Texas MD Anderson Cancer Center, 2005 - 2023

Vice Chair, Institutional Review Board II, The University of Texas MD Anderson Cancer Center, 2005 - 2023

Associate Member, Institutional Review Board lll, The University of Texas MD Anderson Cancer Center, 2005 - 2023

Alternate Member, Institutional Review Board I, The University of Texas MD Anderson Cancer Center, 2004 - 2005

Member, Quality Assurance Oversight Committee (OPRQAOC), The University of Texas MD Anderson Cancer Center, 2000 - 2001

Editorial Activities

Reviewer, Biology of Blood and Marrow Transplant, Reviewed abstract entitled: Feasibility of Reduced-intensity Cord Blood Transplantation as Salvage Therapy for Graft Failure: Results of a Nationwide Survey of 80 Adult Patients

Honors & Awards

1999	Excellence in Data Management, Office of Protocol Research Quality Assurance, The University of Texas MD Anderson Cancer Center

Professional Memberships

Public Responsibility in Medicine and Research

2004 - Present

Association Of Clinical Research Professionals

2003 - 2010

American Association for Cancer Research

2000 - Present

Center for International Blood and Marrow Transplant Research (CIBMTR)

1994 - Present

American Society of Blood and Marrow Transplantation

1994 - Present

American Society of Hematology

1992 - Present

Selected Presentations & Talks

Local Presentations

2015. Protocol Research Challenges. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
2012. Auditing and Quality Improvement. Conference. Clinical Research Administration. Houston, TX, US.

National Presentations

2017. Development and Expansion of Cellular Therapy Registry. Invited. National Marrow Donor Program (NMDP). Minneapolis, MN, US.
2017. Real Time Toxicity Assessment and Fluid Overload. Invited. Memorial Sloan Kettering Cancer Center: BMTToxicity Retreat. New York, NY, US.
2016. CIBMTR Cellular Therapy Registry Forum. Invited. National Marrow Donor Prgram (NMDP). Minneapolis, MN, US.
2016. CIBMTR Cellular Therapy Task Force. Invited. CIBMTR. Wisconsin, IL, US.
2012. CIBMTR Late Outcomes Data Collection Task Force. Invited. CIBMTR. Cincinnati, OH, US.

International Presentations

2018. 1st International Symposium on Hematopoietic Cell Transplantation-Related Toxicities. Invited. Memorial Sloan Kettering Cancer Center. New York, US.

Less

Grant & Contract Support

Date:	2021 - 2026
Title:	A Retrospective Study to Determine the Incidence of, Risk Factors for, and Outcomes of Patients with Transplant-Associated Thrombotic Microangiopathy (TA-TMA) After Allogeneic Hematopoietic Cell Transplantation. A Multi-Center Study”), to be performed in accordance with Omeros’ protocol OMSHSCT-TMA-002
Funding Source:	Omeros Corporation
Role:	Co-I
ID:	#13041498

Date:	2018 - 2023
Title:	Novel Cord Blood Derived Cellular Therapies
Funding Source:	NIH/NCI
Role:	Co-I
ID:	2P01CA148600-11

Date:	2014 - 2022
Title:	MDS/AML Moonshot Cell Therapy Project
Funding Source:	UTMDACC
Role:	Co-I

Date:	2011 - 2018
Title:	Improving Cord Blood Transplantation
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1-P01-CA148600-01, Core A

Date:	2011 - 2016
Title:	MIRA-Cellular Therapy for Cancer
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP110553

Date:	2009 - 2014
Title:	Long-term Cancer Survivor Health Promotion Needs and Disseminated Model Care
Funding Source:	Fred Hutchinson Cancer Research Center
Role:	Collaborator
ID:	R01

Date:	2009 - 2013
Title:	Alloreactive NK Cells
Funding Source:	Commonwealth Foundation
Role:	Co-I

Date:	2002 - 2017
Title:	Improving the Outcomes of Stem Cell Transplantation
Funding Source:	NIH/NHLBI
Role:	Co-I
ID:	U10HL06334

Date:	1997 - 2016
Title:	Therapy of CML--Core A
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	P01 CA49639

Selected Publications

Peer-Reviewed Articles

Alkhunaizi, M, Soto-Lanza, F, Leung, CH, Bhan, N, Bashoura, L, Dickey, BF, Sharifi, H, Cheng, GS, Yanik, G, Rondon, G, Saliba, RM, Chen, GL, Al-Atrash, G, Hosing, C, Kebriaei, P, Popat, UR, Shpall, E, Champlin, RE, Li, L, Alousi, AM, Sheshadri, A. Restrictive Ventilatory Defects Following Hematopoietic Stem Cell Transplant Are Associated With Increased Mortality. Transplantation and Cellular Therapy 31(4):255.e1-255.e10, 2025. e-Pub 2025. PMID: 39921208.
Rahman ZA, Othman T, Saliba RM, Vanegas YAM, Mohty R, Ledesma C, Rondon G, Jain N, Jabbour E, Pullarkat V, Alkhateeb HB, Kantarjian HM, Greipp PT, Nakamura R, Kharfan-Dabaja MA, Champlin RE, Forman SJ, Shpall EJ, Litzow MR, Foran JM, Aldoss I, Koller PB, Kebriaei P. A Multicenter Analysis of Allogeneic Transplant Outcomes in Adults with Philadelphia-Like B-Cell Acute Lymphoblastic Leukemia in First Complete Remission. Transplant Cell Ther 30(12):1197-1205, 2024. e-Pub 2024. PMID: 39332807.
Hayase E, Hayase T, Mukherjee A, Stinson SC, Jamal MA, Ortega MR, Sanchez CA, Ahmed SS, Karmouch JL, Chang CC, Flores II, McDaniel LK, Brown AN, El-Himri RK, Chapa VA, Tan L, Tran BQ, Xiao Y, Fan C, Pham D, Halsey TM, Jin Y, Tsai WB, Prasad R, Glover IK, Enkhbayar A, Mohammed A, Schmiester M, King KY, Britton RA, Reddy P, Wong MC, Ajami NJ, Wargo JA, Shelburne S, Okhuysen PC, Liu C, Fowler SW, Conner ME, Katsamakis Z, Smith N, Burgos da Silva M, Ponce DM, Peled JU, van den Brink MRM, Peterson CB, Rondon G, Molldrem JJ, Champlin RE, Shpall EJ, Lorenzi PL, Mehta RS, Martens EC, Alousi AM, Jenq RR. Bacteroides ovatus alleviates dysbiotic microbiota-induced graft-versus-host disease. Cell Host Microbe 32(9):1621-1636.e6, 2024. e-Pub 2024. PMID: 39214085.
Sharifi H, Bertini CD, Alkhunaizi M, Hernandez MP, Musa Z, Borges C, Turk I, Bashoura L, Dickey BF, Cheng GS, Yanik GA, Galban C, Guo HH, Godoy M, Reinhardt J, Hoffman E, Castro M, Rondon G, Alousi A, Champlin RE, Shpall EJ, Lu Y, Peterson SW, Datta K, Nicolls M, Hsu JL, Sheshadri A. CT strain metrics allow for earlier diagnosis of bronchiolitis obliterans syndrome after hematopoietic cell transplant. Blood Adv 8(19):5156-5165, 2024. e-Pub 2024. PMID: 39163616.
Khawaja F, Ahmed S, Iyer SP, Sassine J, Handley G, Prakash R, VanWierren T, Jackson J, Zubovskaia A, Ramdial J, Rondon G, Patel KK, Spallone A, Ariza-Heredia EJ, Mulanovich V, Angelidakis G, Jiang Y, Chemaly RF. Cytomegaloviral Infections in Recipients of Chimeric Antigen Receptor T-Cell Therapy: An Observational Study With Focus on Oncologic Outcomes. Open Forum Infect Dis 11(8):ofae422, 2024. e-Pub 2024. PMID: 39086466.
Saengboon S, Ciurea S, Popat U, Ramdial J, Bashir Q, Alousi A, Chen J, Rondon G, Olson A, Im J, Hosing C, Shpall E, Champlin R, Srour SA. Long-term outcomes after haploidentical stem cell transplantation for hematologic malignancies. Blood Adv 8(12):3237-3245, 2024. e-Pub 2024. PMID: 38607399.
Febres-Aldana A, Khawaja F, Morado-Aramburo O, Shigle TL, Rondon G, Sassine J, Spallone A, Srinivasan K, Ramdial J, Alousi A, Champlin R, Chen G, Daher M, Rezvani K, Ariza-Heredia EJ, Shpall EJ, Chemaly RF. Mortality in recipients of allogeneic hematopoietic cell transplantation in the era of cytomegalovirus primary prophylaxis: A single center retrospective Experience. Clin Microbiol Infect 30(6):803-809, 2024. e-Pub 2024. PMID: 38460821.
Pasvolsky O, Saliba RM, Popat UR, Alousi A, Mehta R, Yeh J, Al-Atrash G, Adeel M, Ramdial J, Marin D, Rondon G, Kebriaei P, Champlin R, Daver N, Dinardo C, Short NJ, Shpall EJ, Oran B. Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk 24(5):e196-e204, 2024. e-Pub 2024. PMID: 38403505.
Khouri IF, Alzahrani K, Kantarjian H, Milton DR, Gulbis AM, Sasaki K, Jain N, Short NJ, Kadia T, Daher M, Rafei H, Im JS, Marin D, Olson AL, Popat U, Qazilbash M, Ramdial J, Rondon G, Srour S, Kebriaei P, Shpall E, Champlin R, Jabbour EJ. Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial. Am J Hematol 99(5):836-843, 2024. e-Pub 2024. PMID: 38400519.
Malek AE, Al-Juhaishi T, Milton DR, Ramdial JL, Daher M, Olson AL, Srour SA, Alatrash G, Oran B, Mehta RS, Khouri IF, Bashir Q, Shah N, Ciurea SO, Rondon G, Maadani F, Hosing C, Marin D, Kebriaei P, Rezvani K, Nieto Y, Anderlini P, Alousi AM, Faisal MS, Qazilbash MH, Popat UR, Champlin RE, Shpall EJ, Mulanovich VE, Ahmed S. Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis. Bone Marrow Transplant 59(5):699-704, 2024. e-Pub 2024. PMID: 38355908.
Marcoux C, Saliba RM, Wallis W, Khazal S, Ragoonanan D, Rondon G, Tewari P, Popat U, Oran B, Olson A, Bashir Q, Qazilbash M, Alousi A, Hosing C, Nieto Y, Alatrash G, Marin D, Rezvani K, Khouri I, Srour S, Champlin R, Shpall E, Kebriaei P. Incidence and Risk Factors of Early Onset VOD/SOS Differ in Younger vs Older Adults After Stem Cell Transplantation. Blood Adv 8(5):1128-1136, 2024. e-Pub 2024. PMID: 38266155.
Marinos A, Ramdial J, Khawaja F, Saliba RM, Shigle TL, Alousi AM, Rondon G, Chen J, Ledesma C, Champlin RE, Daher M, Chen G, Marin D, Rezvani K, Shpall EJ, Chemaly RF. Hematopoietic cell transplantation can be safely performed after COVID-19. Bone Marrow Transplant 58(12):1410-1412, 2023. e-Pub 2023. PMID: 37726490.
Al-Juhaishi T, Wang Y, Milton DR, Xu-Monette ZY, Jabbour E, Daher M, Im JS, Bashir Q, Iyer SP, Marin D, Olson AL, Popat U, Qazilbash M, Rondon G, Gulbis AM, Champlin RE, Young KH, Khouri IF. Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant. Bone Marrow Transplant 58(9):1000-1007, 2023. e-Pub 2023. PMID: 37198234.
Ostrin EJ, Rider NL, Alousi AM, Irajizad E, Li L, Peng Q, Kim ST, Bashoura L, Arain MH, Noor LZ, Patel N, Mehta R, Popat UR, Hosing C, Jenq RR, Rondon G, Hanash SM, Paczesny S, Shpall EJ, Champlin RE, Dickey BF, Sheshadri A. A Nasal Inflammatory Cytokine Signature Is Associated with Early Graft-versus-Host Disease of the Lung after Allogeneic Hematopoietic Cell Transplantation: Proof of Concept. Immunohorizons 7(6):421-430, 2023. e-Pub 2023. PMID: 37289498.
Zou J, Kongtim P, Oran B, Srour SA, Greenbaum U, Carmazzi Y, Rondon G, Ciurea SO, Ma Q, Shpall EJ, Champlin RE, Cao K. Molecular disparity of HLA-DPB1 is associated with the development of subsequent solid cancer after allogeneic hematopoietic stem cell transplantation. Cancer 129(8):1205-1216, 2023. e-Pub 2023. PMID: 36738229.
Alkhunaizi M, Patel B, Bueno L, Bhan N, Ahmed T, Arain MH, Saliba R, Rondon G, Dickey BF, Bashoura L, Ost DE, Li L, Wang S, Shpall E, Champlin RE, Mehta R, Popat UR, Hosing C, Alousi AM, Sheshadri A. Risk Factors for Bronchiolitis Obliterans Syndrome after Initial Detection of Pulmonary Impairment. Transplant Cell Ther 29(3):204.e1-204.e7, 2023. e-Pub 2023. PMID: 36503180.
Mehta RS, Cao K, Saliba RM, Al-Atrash G, Alousi AM, Lontos K, Marcoux C, Carmazzi Y, Rondon G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Marin D, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial J, Rezvani K, Champlin RE, Shpall EJ. HLA Factors versus Non-HLA Factors for Haploidentical Donor Selection. Transplant Cell Ther 29(3):189-198, 2023. e-Pub 2023. PMID: 36470579.
Ngo-Huang A, Ombres R, Saliba RM, Szewczyk N, Adekoya L, Soones TN, Ferguson J, Fontillas RC, Gulbis AM, Hosing C, Kebriaei P, Lindsay R, Marin DC, Mehta RS, Alousi AM, Srour S, Oran B, Olson AL, Qazilbash MH, Rivera Z, Champlin RE, Shpall EJ, Popat UR. Enhanced Recovery Stem-Cell Transplantation: Multidisciplinary Efforts to Improve Outcomes in Older Adults Undergoing Hematopoietic Stem-Cell Transplant. JCO Oncol Pract 19(3):e417-e427, 2023. e-Pub 2023. PMID: 36626702.
Jenq R, Hayase E, Hayase T, Mukherjee A, Stinson S, Jamal M, Ortega M, Sanchez C, Ahmed S, Karmouch J, Chang CC, Flores I, McDaniel L, Brown A, El-Himri R, Chapa V, Tan L, Tran B, Pham D, Halsey T, Jin Y, Tsai WB, Prasad R, Glover I, Ajami N, Wargo J, Shelburne S, Okhuysen P, Liu C, Fowler S, Conner M, Peterson C, Rondon G, Molldrem JJ, Champlin R, Shpall E, Lorenzi P, Mehta R, Martens E, Alousi A. Bacteroides ovatus alleviates dysbiotic microbiota-induced intestinal graft-versus-host disease. Res Sq, 2023. e-Pub 2023. PMID: 36778495.
Schwabkey ZI, Wiesnoski DH, Chang CC, Tsai WB, Pham D, Ahmed SS, Hayase T, Ortega Turrubiates MR, El-Himri RK, Sanchez CA, Hayase E, Frenk Oquendo AC, Miyama T, Halsey TM, Heckel BE, Brown AN, Jin Y, Raybaud M, Prasad R, Flores I, McDaniel L, Chapa V, Lorenzi PL, Warmoes MO, Tan L, Swennes AG, Fowler S, Conner M, McHugh K, Graf T, Jensen VB, Peterson CB, Do KA, Zhang L, Shi Y, Wang Y, Galloway-Pena JR, Okhuysen PC, Daniel-MacDougall CR, Shono Y, Burgos da Silva M, Peled JU, van den Brink MRM, Ajami N, Wargo JA, Reddy P, Valdivia RH, Davey L, Rondon G, Srour SA, Mehta RS, Alousi AM, Shpall EJ, Champlin RE, Shelburne SA, Molldrem JJ, Jamal MA, Karmouch JL, Jenq RR. Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment. Sci Transl Med 14(671):eabo3445, 2022. e-Pub 2022. PMID: 36383683.
Mehta RS, Saliba RM, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial J, Srour SA, Champlin RE, Rezvani K, Shpall EJ, Alousi AM. Post-Transplantation Cyclophosphamide Versus Tacrolimus and Methotrexate Graft-Versus-Host Disease Prophylaxis for HLA-Matched Donor Transplantation. Transplant Cell Ther 28(10):695.e1-695.e10, 2022. e-Pub 2022. PMID: 35902049.
Hayase E, Hayase T, Jamal MA, Miyama T, Chang CC, Ortega MR, Ahmed SS, Karmouch JL, Sanchez CA, Brown AN, El-Himri RK, Flores II, McDaniel LK, Pham D, Halsey T, Frenk AC, Chapa VA, Heckel BE, Jin Y, Tsai WB, Prasad R, Tan L, Veillon L, Ajami NJ, Wargo JA, Galloway-Peña J, Shelburne S, Chemaly RF, Davey L, Glowacki RWP, Liu C, Rondon G, Alousi AM, Molldrem JJ, Champlin RE, Shpall EJ, Valdivia RH, Martens EC, Lorenzi PL, Jenq RR. Mucus-degrading Bacteroides link carbapenems to aggravated graft-versus-host disease. Cell 185(20):3705-3719.e14, 2022. e-Pub 2022. PMID: 36179667.
Mehta RS, Saliba RM, Hayase E, Jenq RR, Abraham S, Rashid A, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Srour S, Champlin RE, Rezvani K, Shpall EJ, Alousi AM. Mycophenolate Mofetil: A Friend or a Foe with Post-Transplantation Cyclophosphamide and Tacrolimus Prophylaxis in HLA-Matched Donors?. Transplant Cell Ther 28(8):500.e1-500.e10, 2022. e-Pub 2022. PMID: 35662592.
Alatrash G, Saberian C, Bassett R, Thall PF, Ledesma C, Lu Y, Daher M, Valdez BC, Kawedia J, Popat U, Mehta R, Oran B, Nieto Y, Olson A, Anderlini P, Marin D, Hosing C, Alousi AM, Shpall EJ, Rondon G, Chen J, Qazilbash M, Champlin RE, Kebriaei P. Vorinostat combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-term Study Outcomes. Transplant Cell Ther 28(8):501.e1-501.e7, 2022. e-Pub 2022. PMID: 35618218.
Saliba, RM, Srour, S, Greenbaum, U, Ma, Q, Carmazzi, Y, Moller, M, Wood, J, Ciurea, SO, Kongtim, P, Rondon, G, Li, D, Saengboon, S, Alousi, AM, Rezvani, K, Shpall, E, Cao, K, Champlin, RE, Zou, J. SIRPα Mismatch Is Associated With Relapse Protection and Chronic Graft-Versus-Host Disease After Related Hematopoietic Stem Cell Transplantation for Lymphoid Malignancies. Frontiers in immunology 13, 2022. e-Pub 2022. PMID: 35874659.
Steiner RE, Banchs J, Koutroumpakis E, Becnel M, Gutierrez C, Strati P, Pinnix CC, Feng L, Rondon G, Claussen C, Palaskas N, Karimzad K, Ahmed S, Neelapu SS, Shpall E, Wang M, Vega F, Westin J, Nastoupil LJ, Deswal A. Cardiovascular events in patients treated with chimeric antigen receptor t-cell therapy for aggressive B-cell lymphoma. Haematologica 107(7):1555-1566, 2022. e-Pub 2021. PMID: 34758610.
Mehta RS, Saliba RM, Ghanem S, Alousi AM, Rondon G, Anderlini P, Al-Atrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Saini N, Srour SA, Champlin RE, Rezvani K, Shpall EJ. Haploidentical vs Matched Unrelated vs Matched Sibling Donor HCT with Post-Transplantation Cyclophosphamide. Transplant Cell Ther 28(7):395.e1-395.e11, 2022. e-Pub 2022. PMID: 35513252.
Li A, Martens KL, Nguyen D, Basom R, Rondon G, Jin S, Young E, Amos CI, Lee SJ, Davis C, Garcia DA, Champlin R, Shpall E, Kebriaei P, Rojas Hernandez C. External Validation of the HIGH-2-LOW Model: A Predictive Score for Venous Thromboembolism after Allogeneic Transplant. Am J Hematol 97(6):740-748, 2022. e-Pub 2022. PMID: 35266218.
Zou J, Kongtim P, Oran B, Kosmoliaptsis V, Carmazzi Y, Ma J, Li L, Rondon G, Srour S, Copley HC, Partlow D, Ciurea SO, Greenbaum U, Ma Q, Shpall EJ, Champlin RE, Cao K. Refined HLA-DPB1 mismatch with molecular algorithms predicts outcomes in hematopoietic stem cell transplantation. Haematologica 107(4):844-856, 2022. e-Pub 2022. PMID: 34435482.
Akin S, Hosing C, Khouri I, Ahmed S, Alousi A, Fowler N, Joseph J, Truxillo J, Ramdial JL, Maadani F, Rondon G, Daher M, Im JS, Steiner R, Westin J, Iyer SP, Dabaja B, Anderlini P, Popat UR, Qazilbash MH, Flowers CR, Shpall E, Champlin RE, Nieto Y, Srour SA. Autologous Stem Cell Transplantation for Large B-cell Lymphoma with Secondary Central Nervous System Involvement. Blood Adv 6(7):2267-2274, 2022. e-Pub 2022. PMID: 35008100.
Ciurea SO, Kongtim P, Soebbing D, Trikha P, Behbehani G, Rondon G, Olson A, Bashir Q, Gulbis AM, Indreshpal K, Rezvani K, Shpall EJ, Bassett R, Cao K, Martin AS, Devine S, Horowitz M, Pasquini M, Lee DA, Champlin RE. Decrease post-transplant relapse using donor-derived expanded NK-cells. Leukemia 36(1):155-164, 2022. e-Pub 2021. PMID: 34312462.
Bashir Q, Milton DR, Popat UR, Kebriaei P, Hosing C, Khouri IF, Rezvani K, Nieto Y, Oran B, Srour SA, Saini NY, Olson AL, Ahmed S, Al-Atrash G, Rondon G, Konopleva MY, Champlin RE, Shpall EJ, Qazilbash MH, Pemmaraju N. Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Bone Marrow Transplant 57(1):51-56, 2022. e-Pub 2021. PMID: 34629467.
Zou J, Kongtim P, Srour SA, Greenbaum U, Schetelig J, Heidenreich F, Baldauf H, Moore B, Saengboon S, Carmazzi Y, Rondon G, Ma Q, Rezvani K, Shpall EJ, Champlin RE, Ciurea SO, Cao K. Donor selection for KIR alloreactivity is associated with superior survival in haploidentical transplant with PTCy. Front Immunol 13:1033871, 2022. e-Pub 2022. PMID: 36311784.
Yeh J, Whited L, Saliba RM, Rondon G, Banchs J, Shpall E, Champlin R, Popat U. Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era. Blood Adv 5(24):5599-5607, 2021. e-Pub 2021. PMID: 34592759.
Patel R, Ma J, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Daher M, Mehta R, Srour S, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Shpall ES, Champlin RE, Saini N, Qazilbash MH. Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity-score matched analysis. Am J Hematol 96(12):E455-E457, 2021. e-Pub 2021. PMID: 34559916.
Mehta RS, Saliba RM, Alsfeld LC, Jorgensen JL, Wang SA, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Rondon G, Saini N, Srour SA, Rezvani K, Shpall EJ, Champlin RE, Alousi AM. Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther 27(12):1003.e1-1003.e13, 2021. e-Pub 2021. PMID: 34537419.
Khouri IF, Milton DR, Gulbis AM, Jabbour EJ, Nastoupil L, Ledesma C, Anderlini P, Bashir Q, Daher M, Im JS, Iyer SP, Marin D, Mehta RS, Olson AL, Popat UR, Qazilbash M, Saini N, Samaniego F, Rondon G, Medeiros LJ, Champlin RE. Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant. Clin Cancer Res 27(21):5847-5856, 2021. e-Pub 2021. PMID: 34380640.
Ciurea SO, Al Malki MM, Kongtim P, Zou J, Aung FM, Rondon G, Chen J, Taniguchi M, Otoukesh S, Nademanee A, Forman SJ, Champlin R, Gendzekhadze K, Cao K. Treatment of allosensitized patients receiving allogeneic transplantation. Blood Adv 5(20):4031-4043, 2021. e-Pub 2021. PMID: 34474478.
Saliba RM, Greenbaum U, Ma Q, Srour SA, Carmazzi Y, Li L, Oran B, Moller M, Wood J, Ciurea SO, Kongtim P, Rondon G, Partlow D, Li D, Rezvani K, Shpall EJ, Cao K, Champlin RE, Zou J. Mismatch in SIRPα, a regulatory protein in innate immunity, is associated with chronic GVHD in hematopoietic stem cell transplantation. Blood Adv 5(17):3407-3417, 2021. e-Pub 2021. PMID: 34495313.
Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM, Kaur I, Abueg G, Rao S, Chemaly R, Mulanovich V, Al-Atrash G, Alousi AM, Andersson BS, Anderlini P, Bashir Q, Castro KM, Daher M, Galvan IM, Hosing C, Im JS, Jones RB, Kebriaei P, Khouri I, Mehta R, Molldrem J, Nieto Y, Oran B, Popat U, Qazilbash M, Rondon G, Saini N, Spencer B, Srour S, Washington D, Barnett M, Champlin RE, Shpall EJ, Rezvani K. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol 39(24):JCO2002608, 2021. e-Pub 2021. PMID: 33929874.
Yalniz FF, Saliba RM, Greenbaum U, Ramdial J, Popat U, Oran B, Alousi A, Olson A, Alatrash G, Marin D, Rezvani K, Hosing C, Im J, Mehta R, Qazilbash M, Joseph JJ, Rondon G, Kanagal-Shamanna R, Shpall E, Champlin R, Kebriaei P. Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid Leukemia. Transplant Cell Ther 27(8):689-695, 2021. e-Pub 2021. PMID: 34023569.
Kharfan-Dabaja MA, Kumar A, Ayala E, Aljurf M, Nishihori T, Marsh R, Burroughs LM, Majhail N, Al-Homsi AS, Al-Kadhimi ZS, Bar M, Bertaina A, Boelens JJ, Champlin R, Chaudhury S, DeFilipp Z, Dholaria B, El-Jawahri A, Fanning S, Fraint E, Gergis U, Giralt S, Hamilton BK, Hashmi SK, Horn B, Inamoto Y, Jacobsohn DA, Jain T, Johnston L, Kanate AS, Kansagra A, Kassim A, Kean LS, Kitko CL, Knight-Perry J, Kurtzberg J, Liu H, MacMillan ML, Mahmoudjafari Z, Mielcarek M, Mohty M, Nagler A, Nemecek E, Olson TS, Oran B, Perales MA, Prockop SE, Pulsipher MA, Pusic I, Riches ML, Rodriguez C, Romee R, Rondon G, Saad A, Shah N, Shaw PJ, Shenoy S, Sierra J, Talano J, Verneris MR, Veys P, Wagner JE, Savani BN, Hamadani M, Carpenter PA. Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther 27(8):642-649, 2021. e-Pub 2021. PMID: 34304802.
Koller P, Saliba RM, Ledesma C, Rondon G, Popat U, Alousi A, Mehta R, Oran B, Olson A, Hosing C, Qazilbash M, Khouri I, Ciurea S, Shpall E, Jorgensen J, Wang S, Jain N, Jabbour E, Kantarjian H, Champlin R, Konopleva M, Kebriaei P. Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 56(7):1746-1749, 2021. e-Pub 2021. PMID: 33767403.
Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Flowers CR, Tummala S, Ramdial JL, Yalniz FF, Hawkins M, Rezvani K, Champlin RE, Shpall EJ, Neelapu SS, Kebriaei P, Ahmed S. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv 5(14):2799-2806, 2021. e-Pub 2021. PMID: 34264268.
Mehta RS, Bassett R, Rondon G, Overman BJ, Popat UR, Hosing CM, Rezvani K, Qazilbash MH, Anderlini P, Jones RB, Kebriaei P, Marin D, Khouri IF, Oran B, Ciurea SO, Kondo K, Couriel DR, Shpall EJ, Champlin RE, Alousi AM. Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD. Bone Marrow Transplant 56(6):1316-1324, 2021. e-Pub 2021. PMID: 33398094.
Joseph J, Ma J, Hennawy F, Abdulrazzaq MN, Saini N, Patel RD, Hosing CM, Alousi AM, Anderlini P, Popat UR, Qazilbash MH, Shpall EJ, Srour S, Kebriaei P, Bashir Q, Nastoupil LJ, Westin JR, Rondon G, Champlin RE, Andersson BS, Nieto Y, Muzzafar T, Ahmed S. Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Transplant Cell Ther 27(5):404.e1-404.e5, 2021. e-Pub 2021. PMID: 33965178.
Mehta RS, Saliba RM, Jan A, Shigle TL, Wang E, Nieto Y, Ciurea SO, Oran B, Im J, Olson A, Marin D, Qazilbash M, Khouri I, Rondon G, Anderlini P, Rezvani K, Popat U, Kebriaei P, Shpall E, Champlin R, Alousi A. Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease. Transplant Cell Ther 27(3):272.e1-272.e5, 2021. e-Pub 2021. PMID: 33781539.
Sheshadri A, Saliba R, Patel B, Ahmed T, Bueno LC, Arain MH, Mehta RS, Popat UR, Hosing CM, Rondon G, Bashoura L, Dickey BF, Champlin RE, Alousi AM. Azithromycin may increase hematologic relapse rates in matched unrelated donor hematopoietic cell transplant recipients who receive anti-thymocyte globulin, but not in most other recipients. Bone Marrow Transplant 56(3):745-748, 2021. e-Pub 2021. PMID: 33009515.
Srour SA, Saliba RM, Bashir Q, Popat UR, Ahmed S, Mehta RS, Delgado R, Rondon G, Parmar S, Kebriaei P, Hosing C, Manasanch EE, Lee HC, Patel KK, Orlowski RZ, Shpall E, Champlin RE, Qazilbash MH, Nieto Y. Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Transplant Cell Ther 27(3):243.e1-243.e6, 2021. e-Pub 2021. PMID: 33781521.
Saberian C, Abdel-Wahab N, Abudayyeh A, Rafei H, Joseph J, Rondon G, Whited L, Gruschkus S, Fa'ak F, Daher M, Knape C, Safa H, Shoukier M, Suarez-Almazor ME, Marcotulli M, Ludford K, Gulbis AM, Konopleva M, Ohanian M, Ravandi F, Garcia-Manero G, Oran B, Popat UR, Mehta R, Alousi AM, Daver N, Champlin R, Diab A, Al-Atrash G. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. J Immunother Cancer 9(2), 2021. e-Pub 2021. PMID: 33637601.
Saliba RM, Veltri L, Rondon G, Chen J, Al-Atrash G, Alousi A, Martinez C, Augustine L, Hosing CM, Oran B, Rezvani K, Shpall EJ, Kebriaei P, Khouri IF, Popat U, Champlin RE, Ciurea SO. Impact of graft composition on outcomes of haploidentical bone marrow stem cell transplantation. Haematologica 106(1):269-274, 2021. e-Pub 2021. PMID: 32107328.
Abudayyeh A, Lin H, Mamlouk O, Abdelrahim M, Saliba R, Rondon G, Martinez CS, Delgado R, Page V, Rajasekaran A, Sanders PW, Qazilbash M. Impact of autologous stem cell transplantation on long term renal function and associated progression-free and overall survival in multiple myeloma. Leuk Lymphoma 61(13):1-11, 2020. e-Pub 2020. PMID: 32723196.
Oran B, de Lima M, Garcia-Manero G, Thall PF, Lin R, Popat U, Alousi AM, Hosing C, Giralt S, Rondon G, Woodworth G, Champlin RE. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv 4(21):5580-5588, 2020. e-Pub 2020. PMID: 33170934.
Saini N, Marin D, Ledesma C, Delgado R, Rondon G, Popat UR, Bashir Q, Hosing CM, Nieto Y, Alousi AM, Qazilbash MH, Ciurea S, Shpall E, Khouri I, Kantarjian H, Jabbour E, Ravandi F, Champlin RE, Kebriaei P. Impact of TKI maintenance post-allogeneic transplant in Philadelphia positive acute lymphoblastic leukemia. Blood 136(15):1786-1789, 2020. e-Pub 2020. PMID: 32492706.
Saini N, Bashir Q, Milton DR, Tang G, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Mehta R, Srour S, Khouri IF, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. Blood Adv 4(19):4834-4837, 2020. e-Pub 2020. PMID: 33027527.
Sheshadri A, Alousi A, Bashoura L, Stolar K, Baghaie S, Arain MH, Noor L, Balagani A, Jain A, Blanco D, Ortiz A, Peterson SK, Langhals R, Taylor M, Stenzler A, Mehta RS, Popat UR, Hosing C, Rondon G, Shen F, Li L, Cheng GS, Ost DE, Champlin RE, Dickey BF. Feasibility and Reliability of Home-based Spirometry Telemonitoring in Allogeneic Hematopoietic Cell Transplant Recipients. Ann Am Thorac Soc 17(10):1329-1333, 2020. e-Pub 2020. PMID: 32614241.
Zou J, Ciurea SO, Kongtim P, Yi M, Carmazzi Y, Rondon G, Srour S, Partlow D, Champlin RE, Cao K. Molecular disparity in human leukocyte antigens is associated with outcomes in haploidentical stem cell transplantation. Blood Adv 4(15):3474-3485, 2020. e-Pub 2020. PMID: 32726398.
Popat U, Mehta RS, Bassett R, Kongtim P, Chen J, Alousi AM, Anderlini P, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Lindsay R, Nieto Y, Olson A, Oran B, Qazilbash MH, Rondon G, Shpall EJ, Verstovsek S, Andersson BS, Champlin RE. Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial. Biol Blood Marrow Transplant 26(8):1439-1445, 2020. e-Pub 2020. PMID: 32438043.
Srour SA, Kongtim P, Rondon G, Chen J, Petropoulos D, Ramdial J, Popat U, Kebriaei P, Qazilbash M, Shpall EJ, Champlin RE, Ciurea SO. Haploidentical transplants for patients with relapse after the first allograft. Am J Hematol. e-Pub 2020. PMID: 32619033.
Kongtim P, Bittencourt M, Srour SA, Ramdial J, Rondon G, Chen J, Khouri I, Betul O, Popat U, Olson A, Bashir Q, Shpall EJ, Kebriaei P, Champlin RE, Ciurea SO. Haploidentical transplants for patients with graft failure after the first allograft. Am J Hematol. e-Pub 2020. PMID: 32602112.
Abudayyeh A, Lin H, Abdelrahim M, Rondon G, Andersson BS, Martinez CS, Page VD, Tarrand JJ, Kontoyiannis DP, Marin D, Oran B, Olson A, Jones R, Popat U, Champlin RE, Chemaly RF, Shpall EJ, Rezvani K. Development and validation of a risk assessment tool for BKPyV Replication in allogeneic stem cell transplant recipients. Transpl Infect Dis:e13395. e-Pub 2020. PMID: 32602954.
Ciurea SO, Kongtim P, Hasan O, Ramos Perez JM, Torres J, Rondon G, Champlin RE. Validation of a Hematopoietic Cell Transplant-Composite Risk (HCT-CR) Model for Post-Transplant Survival Prediction in Patients with Hematologic Malignancies. Clin Cancer Res 26(10):2404-2410, 2020. e-Pub 2020. PMID: 32019857.
Varma A, Rondon G, Srour SA, Chen J, Ledesma C, Champlin RE, Ciurea SO, Saliba RM. Endothelial Activation and Stress Index (EASIX) at Admission Predicts Fluid Overload in Recipients of Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 26(5):1013-1020, 2020. e-Pub 2020. PMID: 32045652.
Varma A, Abraham SC, Mehta RS, Saini NY, Honhar M, Rashid M, Chen J, Srour SA, Bashir Q, Rondon G, Oran B, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Marin D, Khouri IF, Ciurea SO, Qazilbash MH, Rezvani K, Anderlini P, Andersson BS, Shpall EJ, Champlin RE, Popat UR. Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. Blood Adv 4(7):1296-1306, 2020. e-Pub 2020. PMID: 32236526.
Varma A, Sui D, Milton DR, Tang G, Saini N, Hasan O, Mukherjee A, Joseph JJ, Bashir Q, Rondon G, Srour S, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Mehta R, Khouri IF, Ahmed H, Iyer S, Weber DM, Thomas SK, Manasanch E, Lee HC, Patel K, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Multiple Myeloma With Chromosome 1q Gain and 1p Deletion After Autologous Hematopoietic Stem Cell Transplantation: propensity-score matched analysis: Outcome of 1q+/1p- MM pts after auto-HCT. Biol Blood Marrow Transplant 26(4):665-671, 2020. e-Pub 2020. PMID: 31881283.
Srour SA, Singh H, McCarty J, de Groot E, Huls H, Rondon G, Qazilbash M, Ciurea S, Bardelli G, Buck J, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Wierda WG, Kantarjian H, Champlin RE, Cooper LJ, Kebriaei P. Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas. Blood 135(11):862-865, 2020. e-Pub 2020. PMID: 31961918.
Ciurea SO, Kongtim P, Varma A, Rondon G, Chen J, Srour S, Bashir Q, Alousi A, Mehta R, Oran B, Popat U, Hosing C, Olson A, Daver N, Konopleva M, Champlin RE. Is There an Optimal Conditioning for Older Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation?. Blood 135(6):449-452, 2020. e-Pub 2020. PMID: 31826244.
El Haddad L, Ghantoji SS, Park AK, Batista MV, Schelfhout J, Hachem J, Lobo Y, Jiang Y, Rondon G, Champlin R, Chemaly RF. Clinical and economic burden of pre-emptive therapy of cytomegalovirus infection in hospitalized allogeneic hematopoietic cell transplant recipients. J Med Virol 92(1):86-95, 2020. e-Pub 2020. PMID: 31448830.
Kongtim P, Hasan O, Perez JMR, Varma A, Wang SA, Patel KP, Chen J, Rondon G, Srour S, Bashir Q, Qazilbash M, Mehta R, Shpall EJ, Alousi A, Khouri I, Kebriaei P, Popat U, Champlin RR, Ciurea SO. Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 26(1):197-203, 2020. e-Pub 2020. PMID: 31518645.
Ciurea SO, Varma A, Kongtim P, Srour S, Bashir Q, Alousi AM, Mehta RS, Oran B, Popat U, Hosing C, Rondon G, Chen J, Olson AL, Konopleva MY, Champlin RE. Optimal Conditioning for Older Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Propensity Score Analysis. Blood 134(Supplement_1):42, 2019. e-Pub 2019. PMID: 31724003.
Saini N, Ma J, Milton DR, Patel R, Varma A, Bashir Q, Delgado R, Mukherjee A, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Tang G, Mehta R, Srour S, Khouri IF, Iyer S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. Clin Cancer Res 25(22):6781-6787, 2019. e-Pub 2019. PMID: 31481508.
Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Mukherjee A, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia. Ann Hematol 98(9):2233-2235, 2019. e-Pub 2019. PMID: 31243571.
Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Hosing CM, Oran B, Bashir Q, Olson A, Nieto Y, Alousi A, Kebriaei P, Srour S, Mehta R, Anderlini P, Shpall EJ, Qazilbash MH, Khouri IF, Fayad L, Lee H, Fowler N, Parmar S, Westin J, Hagemeister F, Champlin RE, Ciurea SO. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant 25(7):1340-1346, 2019. e-Pub 2019. PMID: 30763728.
Chamoun K, Milton DR, Ledesma C, Young KH, Jabbour EJ, Alatrash G, Anderlini P, Bashir Q, Ciurea SO, Marin D, Molldrem JJ, Olson AL, Oran B, Popat UR, Rondon G, Champlin RE, Gulbis AM, Khouri IF. Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results. Biol Blood Marrow Transplant 25(7):1347-1354, 2019. e-Pub 2019. PMID: 30826465.
Ciurea SO, Hansrivijit P, Ciurea AM, Hymes S, Chen J, Rondon G, Hosing C, Popat U, Champlin RE. Curative potential of hematopoietic stem cell transplantation for advanced psoriasis. Am J Hematol 94(6):E176-E180, 2019. e-Pub 2019. PMID: 30900768.
Kongtim P, Parmar S, Milton DR, Perez JMR, Rondon G, Chen J, Chilkulwar AR, Al-Atrash G, Alousi A, Andersson BS, Im JS, Hosing CM, Bashir Q, Khouri I, Kebriaei P, Oran B, Popat U, Champlin R, Ciurea SO. Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant 54(6):839-848, 2019. e-Pub 2019. PMID: 30258129.
van Besien K, Artz A, Champlin RE, Guarneri D, Bishop MR, Chen J, Gergis U, Shore T, Liu H, Rondon G, Mayer SA, Srour SA, Stock W, Ciurea SO. Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. Blood Adv 3(12):1858-1867, 2019. e-Pub 2019. PMID: 31217161.
Ghobadi A, Milton DR, Gowda L, Rondon G, Chemaly RF, Hamdi A, Alousi A, Afrough A, Oran B, Ciurea S, Kebriaei P, Popat UR, Qazilbash MH, Shpall EJ, Champlin RE, Bashir Q. HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant. Curr Res Transl Med 67(2):51-55, 2019. e-Pub 2019. PMID: 30683577.
Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MH. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol 6(5):e266-e275, 2019. e-Pub 2019. PMID: 30910541.
Galloway-Peña JR, Peterson CB, Malik F, Sahasrabhojane PV, Shah DP, Brumlow CE, Carlin LG, Chemaly RF, Im JS, Rondon G, Felix E, Veillon L, Lorenzi PL, Alousi AM, Jenq RR, Kontoyiannis DP, Shpall EJ, Shelburne SA, Okhuysen PC. Fecal Microbiome, Metabolites, and Stem Cell Transplant Outcomes: A Single-Center Pilot Study. Open Forum Infect Dis 6(5):ofz173, 2019. e-Pub 2019. PMID: 31065565.
Shah MV, Saliba RM, Rondon G, Chen J, Soebbing D, Rus I, Alousi A, Oran B, Kebriaei P, Qazilbash M, Parmar S, Hosing C, Khouri IF, Popat UR, Champlin RE, Ciurea SO. Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation. Bone Marrow Transplant 54(4):601-606, 2019. e-Pub 2019. PMID: 30337700.
Sheshadri A, Chemaly RF, Alousi AM, Shah PK, Rondon G, Bashoura L, Kmeid J, Azzi J, Blanco DW, Kaous M, Dickey BF, Champlin RE, Shah DP. Pulmonary Impairment after Respiratory Viral Infections Is Associated with High Mortality in Allogeneic Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 25(4):800-809, 2019. e-Pub 2019. PMID: 30521974.
Veltri L, Rezvani K, Oran B, Mehta R, Rondon G, Kebriaei P, Popat U, Nieto Y, Hosing C, Qazilbash M, Khouri I, Shpall E, Champlin R, Marin D. Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia. Biol Blood Marrow Transplant 25(3):505-514, 2019. e-Pub 2019. PMID: 30308325.
Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome. Am J Hematol 94(3):E72-E74, 2019. e-Pub 2019. PMID: 30548467.
Saini NY, Patel R, Varma A, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan-based autologous transplant in octogenarian multiple myeloma patients. Am J Hematol 94(1):E2-E5, 2019. e-Pub 2019. PMID: 30300461.
Afrough A, Saliba RM, Hamdi A, Honhar M, Varma A, Cornelison AM, Rondon G, Parmar S, Shah ND, Bashir Q, Hosing C, Popat U, Weber DM, Thomas S, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 24(11):2197-2203, 2018. e-Pub 2018. PMID: 30016656.
Ciurea SO, Bittencourt MCB, Milton DR, Cao K, Kongtim P, Rondon G, Chen J, Konopleva M, Perez JMR, El Shazly MF, Aljadayeh M, Alvarez M, Im J, Al-Atrash G, Mehta R, Popat U, Bashir Q, Oran B, Hosing CM, Khouri IF, Kebriaei P, Champlin RE. Is a matched unrelated donor search needed for all allogeneic transplant candidates?. Blood Adv 2(17):2254-2261, 2018. e-Pub 2018. PMID: 30206098.
Malek E, Gupta V, Creger R, Caimi P, Vatsayan A, Covut F, Bashir Q, Champlin R, Delgado R, Rondon G, Cooper B, de Lima M, Lazarus HM, Qazilbash M. Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma. Leuk Lymphoma 59(8):1-8, 2018. e-Pub 2018. PMID: 29295650.
Ciurea SO, Chilkulwar A, Saliba RM, Chen J, Rondon G, Patel KP, Khogeer H, Shah AR, Randolph BV, Perez JMR, Popat U, Hosing CM, Bashir Q, Mehta R, Al-Atrash G, Im J, Khouri IF, Kebriaei P, Champlin RE. Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations. Blood 131(26):2989-2992, 2018. e-Pub 2018. PMID: 29769261.
Ciurea SO, Shah MV, Saliba RM, Gaballa S, Kongtim P, Rondon G, Chen J, Wallis W, Cao K, Konopleva M, Daver N, Cortes J, Ravandi F, Alousi A, Ahmed S, Popat U, Parmar S, Bashir Q, Betul O, Hosing C, Shpall EJ, Rezvani K, Khouri IF, Kebriaei P, Champlin RE. Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant 24(6):1232-1236, 2018. e-Pub 2018. PMID: 28918304.
Tamari R, Oran B, Hilden P, Maloy M, Kongtim P, Papadopoulos EB, Rondon G, Jakubowski AA, Andersson BS, Devlin SM, Ahmed S, Popat UR, Ponce D, Chen J, Sauter C, Young JW, de Lima M, Perales MA, O'Reilly RJ, Giralt SA, Champlin RE, Castro-Malaspina H. Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 24(5):1079-1087, 2018. e-Pub 2018. PMID: 29325829.
Ciurea SO, Labopin M, Socie G, Volin L, Passweg J, Chevallier P, Beelen D, Milpied N, Blaise D, Cornelissen JJ, Fegueux N, Polge E, Kongtim P, Rondon G, Esteve J, Mohty M, Savani BN, Champlin RE, Nagler A. Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center. Cancer 124(10):2134-2141, 2018. e-Pub 2018. PMID: 29469961.
Pundole X, Murphy WA, Ebede CC, Karim E, Manocha S, Don-Pedro D, Rondon G, Leung CH, Liu S, Du XL, Champlin RE, Lu H. Fracture risk prediction using FRAX in patients following hematopoietic stem cell transplantation. Arch Osteoporos 13(1):38, 2018. e-Pub 2018. PMID: 29619576.
Oran B, Saliba RM, Carmazzi Y, de Lima M, Rondon G, Ahmed S, Alousi A, Andersson BS, Anderlini P, Alvarez M, Bashir Q, Ciurea S, Fernandez-Vina M, Hosing C, Kebriaei P, Korbling M, Cano P, Khouri I, Marin D, Nieto Y, Olson A, Popat U, Rezvani K, Qazilbash M, Shpall EJ, Champlin RE, Cao K. Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion. Blood 131(11):1248-1257, 2018. e-Pub 2018. PMID: 29386198.
Ragon BK, Mehta RS, Gulbis AM, Saliba RM, Chen J, Rondon G, Popat UR, Nieto Y, Oran B, Olson AL, Patel K, Hosing CM, Qazilbash MH, Shah N, Kebriaei P, Shpall EJ, Champlin RE, Alousi AM. Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit. Bone Marrow Transplant 53(3):315-325, 2018. e-Pub 2018. PMID: 29269797.
Hammerstrom AE, Lombardi LR, Pingali SR, Rondon G, Chen J, Milton DR, Chemaly RF, Champlin RE, Gulbis A, Ciurea SO. Prevention of CMV Reactivation in Haploidentical Stem Cell Transplantation. Biol Blood Marrow Transplant 24(2):353-358, 2018. e-Pub 2018. PMID: 28986189.
Mohyuddin GR, Faisal MS, Badar T, Shah N, Bashir Q, Patel KK, Hosing C, Popat UR, Rondon G, Delgado R, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH. A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. Leuk Lymphoma 59(2):1-4, 2018. e-Pub 2018. PMID: 28673185.
Shah MV, Jorgensen JL, Saliba RM, Wang SA, Alousi AM, Andersson BS, Bashir Q, Ciurea SO, Kebriaei P, Marin D, Patel KP, Popat UR, Rezvani K, Rondon G, Shpall EJ, Champlin RE, Oran B. Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia. Biol Blood Marrow Transplant. e-Pub 2018. PMID: 29448058.
Brammer JE, Chihara D, Poon LM, Caimi P, de Lima M, Ledesma C, Rondon G, Ciurea SO, Nieto Y, Fanale M, Dabaja B, Maziarz RT, Champlin RE, Hosing C, Oki Y. Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes. Clin Lymphoma Myeloma Leuk 18(1):e41-e50, 2018. e-Pub 2018. PMID: 29277360.
Cao K, Marin D, Sekine T, Rondon G, Zhao W, Smith NT, Daher M, Wang Q, Li L, Saliba RM, Pingali R, Popat U, Hosing C, Olson A, Oran B, Basar R, Mehta RS, Champlin R, Shpall EJ, Rezvani K. Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation After Double Cord Blood Transplantation. Front Immunol 9:2444, 2018. e-Pub 2018. PMID: 30405633.
Rondón G, Saliba RM, Chen J, Ledesma C, Alousi AM, Oran B, Hosing CM, Kebriaei P, Khouri IF, Shpall EJ, Popat UR, Champlin RE, Ciurea SO. Impact of Fluid Overload as New Toxicity Category on Hematopoietic Stem Cell Transplantation Outcomes. Biol Blood Marrow Transplant 23(12):2166-2171, 2017. e-Pub 2017. PMID: 28844946.
Im JS, Abraham SC, Saliba RM, Rondon G, Ross WA, Rashid A, Shpall EJ, Popat U, Qazilbash MH, Hosing C, Oran B, Shah N, Tewari P, Nieto Y, Kebriaei P, Champlin RE, Alousi AM. Histologic Grade 1 is Associated With Increased Nonrelapsed Mortality in Lower Gastrointestinal Graft Versus Host Disease. Am J Surg Pathol 41(11):1483-1490, 2017. e-Pub 2017. PMID: 28834808.
Ciurea SO, Schafer JR, Bassett R, Denman CJ, Cao K, Willis D, Rondon G, Chen J, Soebbing D, Kaur I, Gulbis A, Ahmed S, Rezvani K, Shpall EJ, Lee DA, Champlin RE. Phase 1 clinical trial using mbIL21 ex-vivo expanded donor-derived NK cells after haploidentical transplantation. Blood 130(16):1857-1868, 2017. e-Pub 2017. PMID: 28835441.
Hwang JP, Suarez-Almazor ME, Cantor SB, Barbo A, Lin HY, Ahmed S, Chavez-MacGregor M, Donato-Santana C, Eng C, Ferrajoli A, Fisch MJ, McLaughlin P, Simon GR, Rondon G, Shpall EJ, Lok AS. Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy. Cancer 123(17):3367-3376, 2017. e-Pub 2017. PMID: 28518219.
Bachegowda LS, Shah MV, Veltri LW, Tanase A, Popat U, Anderlini P, Chen J, Rondon G, Champlin RE, Ciurea SO. HLA-mismatched bone marrow transplantation in severe aplastic anemia. Bone Marrow Transplant 52(9):1347-1348, 2017. e-Pub 2017. PMID: 28692030.
Yucel OK, Saliba RM, Rondon G, Ahmed S, Alousi A, Bashir Q, Ciurea SO, Popat U, Khouri I, Marin D, Rezvani K, Kebriaei P, Shpall EJ, Champlin RE, Oran B. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogenic stem cell transplantation using reduced intensity conditioning. Cancer 123(14):2661-2670, 2017. e-Pub 2017. PMID: 28324640.
Bayraktar UD, Milton DR, Shpall EJ, Rondon G, Price KJ, Champlin RE, Nates JL. Prognostic Index for Critically Ill Allogeneic Transplantation Patients. Biol Blood Marrow Transplant 23(6):991-996, 2017. e-Pub 2017. PMID: 28263919.
Nieto Y, Valdez BC, Pingali SR, Bassett R, Delgado R, Nguyen J, Shah N, Popat U, Jones RB, Andersson BS, Gulbis A, Ahmed S, Bashir Q, Parmar S, Patel K, Myers A, Rondon G, Orlowski RZ, Champlin R, Qazilbash M. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. Lancet Haematol 4(6):e283-e292, 2017. e-Pub 2017. PMID: 28522110.
Bachegowda LS, Saliba RM, Ramlal R, Kongtim P, Chen J, Rondon G, Wallis W, Alousi A, Ahmed S, Hosing CM, Parmar S, Qazilbash M, Khouri IF, Bashir Q, Oran B, Popat U, Shpall EJ, Marin D, Rezvani K, Kebriaei P, Champlin RE, Ciurea SO. Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation. Blood 129(22):3031-3033, 2017. e-Pub 2017. PMID: 28351938.
Gunther JR, Rahman AR, Dong W, Yehia ZA, Kebriaei P, Rondon G, Pinnix CC, Milgrom SA, Allen PK, Dabaja BS, Smith GL. Craniospinal irradiation prior to stem cell transplant for hematologic malignancies with CNS involvement: Effectiveness and toxicity after photon or proton treatment. Pract Radiat Oncol. e-Pub 2017. PMID: 28666906.
Maher OM, Silva JG, Wu J, Liu D, Cooper LJ, Tarek N, Worth L, Lee DA, Petropoulos D, Franklin AR, Zweidler-Mckay P, Wells RJ, Rondon G, Champlin RE, Tewari P. Outcomes of children, adolescents, and young adults following allogeneic stem cell transplantation for secondary acute myeloid leukemia and myelodysplastic syndromes-The MD Anderson Cancer Center experience. Pediatr Transplant 21(3), 2017. e-Pub 2017. PMID: 28160352.
Gettys SC, Gulbis A, Wilhelm K, Sasaki K, Dinh Y, Rondon G, Qazilbash MH. Modified CVAD and modified CBAD compared to high-dose cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma. Eur J Haematol 98(4):388-392, 2017. e-Pub 2017. PMID: 28009447.
Andersson BS, Thall PF, Valdez BC, Milton DR, Al-Atrash G, Chen J, Gulbis A, Chu D, Martinez C, Parmar S, Popat U, Nieto Y, Kebriaei P, Alousi A, de Lima M, Rondon G, Meng QH, Myers A, Kawedia J, Worth LL, Fernandez-Vina M, Madden T, Shpall EJ, Jones RB, Champlin RE. Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients. Bone Marrow Transplant 52(4):580-587, 2017. e-Pub 2017. PMID: 27991894.
Gaballa S, Saliba R, Oran B, Brammer JE, Chen J, Rondon G, Alousi AM, Kebriaei P, Marin D, Popat UR, Andersson BS, Shpall EJ, Jabbour E, Daver N, Andreeff M, Ravandi F, Cortes J, Patel K, Champlin RE, Ciurea SO. Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation. Am J Hematol 92(4):331-337, 2017. e-Pub 2017. PMID: 28052408.
Kongtim P, Adekola K, Milton DR, Ramlal R, Jimenez A, Chen J, Rondon G, Ahmed S, Kebriaei P, Betul O, Hosing CM, Popat U, Khouri I, Jabbour E, Cortes JE, Kantarjian HM, Champlin RE, Ciurea SO. Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Leukemia. e-Pub 2017. PMID: 28400618.
El Boghdadly Z, Oran B, Jiang Y, Rondon G, Champlin R, Kontoyiannis DP. Pretransplant chest computed tomography screening in asymptomatic patients with leukemia and myelodysplastic syndrome. Bone Marrow Transplant 52(3):476-479, 2017. e-Pub 2017. PMID: 27941772.
Abudayyeh A, Hamdi A, Abdelrahim M, Lin H, Page VD, Rondon G, Andersson BS, Afrough A, Martinez CS, Tarrand JJ, Kontoyiannis DP, Marin D, Gaber AO, Oran B, Chemaly RF, Ahmed S, Abudayyeh I, Olson A, Jones R, Popat U, Champlin RE, Shpall EJ, Rezvani K. Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipients. Transpl Infect Dis 19(1), 2017. e-Pub 2017. PMID: 27862740.
Srour SA, Milton DR, Bashey A, Karduss-Urueta A, Al Malki MM, Romee R, Solomon S, Nademanee A, Brown S, Slade M, Perez R, Rondon G, Forman SJ, Champlin RE, Kebriaei P, Ciurea SO. Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant 23(2):318-324, 2017. e-Pub 2017. PMID: 27856368.
Kebriaei P, Bassett R, Lyons G, Valdez B, Ledesma C, Rondon G, Oran B, Ciurea S, Alousi A, Popat U, Patel K, Ahmed S, Olson A, Bashir Q, Shah N, Jones R, Marin D, Rezvani K, Nieto Y, Khouri I, Qazilbash M, Hosing C, Shpall E, Champlin RE, Andersson BS. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. Biol Blood Marrow Transplant 23(2):285-292, 2017. e-Pub 2017. PMID: 27816651.
Brammer JE, Khouri I, Marin D, Ledesma C, Rondon G, Ciurea SO, Nieto Y, Champlin RE, Hosing C, Kebriaei P. Stem cell transplantation outcomes in lymphoblastic lymphoma. Leuk Lymphoma 58(2):366-371, 2017. e-Pub 2017. PMID: 27348707.
Oran B, Jorgensen JL, Marin D, Wang S, Ahmed S, Alousi AM, Andersson BS, Bashir Q, Bassett R, Lyons G, Chen J, Rezvani K, Popat U, Kebriaei P, Patel K, Rondon G, Shpall EJ, Champlin RE. Pretransplantion minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. Haematologica 102(1):110-117, 2017. e-Pub 2017. PMID: 27540139.
Bock F, Lu G, Srour SA, Gaballa S, Lin HY, Baladandayuthapani V, Honhar M, Stich M, Shah ND, Bashir Q, Patel K, Popat U, Hosing C, Korbling M, Delgado R, Rondon G, Shah JJ, Thomas SK, Manasanch EE, Isermann B, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 22(12):2159-2164, 2016. e-Pub 2016. PMID: 27638366.
Gaballa S, Ge I, El Fakih R, Brammer JE, Kongtim P, Tomuleasa C, Wang SA, Lee D, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom A, Lombardi L, Alatrash G, Korbling M, Oran B, Kebriaei P, Ahmed S, Shah N, Rezvani K, Marin D, Bashir Q, Alousi A, Nieto Y, Qazilbash M, Hosing C, Popat U, Shpall EJ, Khouri I, Champlin RE, Ciurea SO. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer 122(21):3316-3326, 2016. e-Pub 2016. PMID: 27404668.
Gaballa S, Saliba RM, Srour S, Lu G, Brammer JE, Shah N, Bashir Q, Patel K, Bock F, Parmar S, Hosing C, Popat U, Delgado R, Rondon G, Shah JJ, Manasanch EE, Orlowski RZ, Champlin R, Qazilbash MH. Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. Am J Hematol 91(10):E442-7, 2016. e-Pub 2016. PMID: 27420405.
Alatrash G, Thall PF, Valdez BC, Fox PS, Ning J, Garber HR, Janbey S, Worth LL, Popat U, Hosing C, Alousi AM, Kebriaei P, Shpall EJ, Jones RB, de Lima M, Rondon G, Chen J, Champlin RE, Andersson BS. Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant 22(10):1792-800, 2016. e-Pub 2016. PMID: 27377901.
Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, Jena B, Dawson MJ, Kumaresan PR, Su S, Maiti S, Dai J, Moriarity B, Forget MA, Senyukov V, Orozco A, Liu T, McCarty J, Jackson RN, Moyes JS, Rondon G, Qazilbash M, Ciurea S, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Kantarjian H, Keating M, Wierda W, Do KA, Largaespada DA, Lee DA, Hackett PB, Champlin RE, Cooper LJ. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest 126(9):3363-76, 2016. e-Pub 2016. PMID: 27482888.
Thompson PA, Perera T, Marin D, Oran B, Popat U, Qazilbash M, Shah N, Parmar S, Rezvani K, Olson A, Kebriaei P, Anderlini P, Rondon G, Alousi A, Ciurea S, Champlin RE, Bajel A, Szer J, Shpall EJ, Ritchie D, Hosing CM. Double Umbilical Cord Blood Transplantation (dUCB) is effective therapy for relapsed or refractory Hodgkin Lymphoma. Leuk Lymphoma 57(7):1-23, 2016. e-Pub 2016. PMID: 26472485.
Lee DA, Denman CJ, Rondon G, Woodworth G, Chen J, Fisher T, Kaur I, Fernandez-Vina M, Cao K, Ciurea S, Shpall EJ, Champlin RE. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial. Biol Blood Marrow Transplant 22(7):1290-8, 2016. e-Pub 2016. PMID: 27090958.
Milgrom SA, Nieto Y, Pinnix CC, Smith GL, Wogan CF, Rondon G, Medeiros LJ, Kebriaei P, Dabaja BS. Graft-versus-host disease after radiation therapy in patients who have undergone allogeneic stem cell transplantation: two case reports. J Med Case Rep 10:209, 2016. e-Pub 2016. PMID: 27465468.
Sekine T, Marin D, Cao K, Li L, Mehta P, Shaim H, Sobieski C, Jones R, Oran B, Hosing C, Rondon G, Alsuliman A, Paust S, Andersson B, Popat U, Kebriaei P, Muftuoglu M, Basar R, Kondo K, Nieto Y, Shah N, Olson A, Alousi A, Liu E, Sarvaria A, Parmar S, Armstrong-James D, Imahashi N, Molldrem J, Champlin R, Shpall EJ, Rezvani K. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood 128(2):297-312, 2016. e-Pub 2016. PMID: 27247137.
Aung FM, Lichtiger B, Rondon G, Yin CC, Alousi A, Ahmed S, Andersson BS, Bashir Q, Ciurea SO, Hosing C, Jones R, Kebriaei P, Khouri I, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Shpall EJ, Champlin RE, Popat U. Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. Biol Blood Marrow Transplant 22(5):961-5, 2016. e-Pub 2016. PMID: 26921820.
Abudayyeh A, Hamdi A, Lin H, Abdelrahim M, Rondon G, Andersson BS, Afrough A, Martinez CS, Tarrand JJ, Kontoyiannis DP, Marin D, Gaber AO, Salahudeen A, Oran B, Chemaly RF, Olson A, Jones R, Popat U, Champlin RE, Shpall EJ, Winkelmayer WC, Rezvani K. Symptomatic BK Virus Infection Is Associated with Kidney Function Decline and Poor Overall Survival in Allogeneic Hematopoietic Stem Cell Recipients. Am J Transplant 16(5):1492-502, 2016. e-Pub 2016. PMID: 26608093.
Mehta RS, Saliba RM, Chen J, Rondon G, Hammerstrom AE, Alousi A, Qazilbash M, Bashir Q, Ahmed S, Popat U, Hosing C, Khouri I, Shpall EJ, Champlin RE, Ciurea SO. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. Br J Haematol 173(3):444-55, 2016. e-Pub 2016. PMID: 26947769.
Bayraktar UD, Milton DR, Guindani M, Rondon G, Chen J, Al-Atrash G, Rezvani K, Champlin R, Ciurea SO. Optimal Threshold and Time of Absolute Lymphocyte Count Assessment for Outcome Prediction after Bone Marrow Transplantation. Biol Blood Marrow Transplant 22(3):505-13, 2016. e-Pub 2016. PMID: 26524730.
Jacobs RW, Saliba RM, Sasaki K, Farhan S, Armas A, Shah ND, Bashir Q, Qureshi S, Rondon G, Hosing C, Popat U, Parmar S, Shah JJ, Wang M, Weber DM, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk. e-Pub 2015. PMID: 26702475.
Lee HC, Saliba RM, Rondon G, Chen J, Charafeddine Y, Medeiros LJ, Alatrash G, Andersson BS, Popat U, Kebriaei P, Ciurea S, Oran B, Shpall E, Champlin R. Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes. Biol Blood Marrow Transplant 21(11):1948-54, 2015. e-Pub 2015. PMID: 26183077.
Oran B, Cao K, Saliba RM, Rezvani K, de Lima M, Ahmed S, Hosing CM, Popat UR, Carmazzi Y, Kebriaei P, Nieto Y, Rondon G, Willis D, Shah N, Parmar S, Olson A, Moore B, Marin D, Mehta R, Fernández-Viña M, Champlin RE, Shpall EJ. BETTER ALLELE-LEVEL MATCHING IMPROVES TRANSPLANT RELATED MORTALITY AFTER DOUBLE CORD BLOOD TRANSPLANTATION. Haematologica 100(10):1361-70, 2015. e-Pub 2015. PMID: 26250579.
Kongtim P, Popat U, Jimenez A, Gaballa S, El Fakih R, Rondon G, Chen J, Bueso-Ramos C, Borthakur G, Pemmaraju N, Garcia-Manero G, Kantarjian H, Alousi A, Hosing C, Anderlini P, Khouri IF, Kebriaei P, Andersson BS, Oran B, Rezvani K, Marin D, Shpall EJ, Champlin RE, Ciurea SO. Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia. Biol Blood Marrow Transplant. e-Pub 2015. PMID: 26343946.
Ciurea SO, Thall PF, Milton DR, Barnes TH, Kongtim P, Carmazzi Y, López AA, Yap DY, Popat U, Rondon G, Lichtiger B, Aung F, Afshar-Kharghan V, Ma Q, Fernández-Viña M, Champlin RE, Cao K. Complement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 21(8):1392-8, 2015. e-Pub 2015. PMID: 25985919.
Oran B, Jimenez AM, De Lima M, Popat UR, Bassett R, Andersson BS, Borthakur G, Bashir Q, Chen J, Ciurea SO, Jabbour E, Cortes J, Kebriaei P, Khouri IF, Qazilbash MH, Ravandi F, Rondon G, Lu X, Shpall EJ, Champlin RE. Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 21(8):1405-12, 2015. e-Pub 2015. PMID: 25840338.
Afrough A, Saliba RM, Hamdi A, El Fakih R, Varma A, Dinh YT, Rondon G, Cornelison AM, Shah ND, Bashir Q, Shah JJ, Hosing C, Popat U, Orlowski RZ, Champlin RE, Parmar S, Qazilbash MH. Outcome of Patients with Immunoglobulin Light Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 21(8):1413-7, 2015. e-Pub 2015. PMID: 25842049.
Saliba RM, Rezvani K, Leen A, Jorgensen J, Shah N, Hosing C, Parmar S, Oran B, Olson A, Rondon G, Chen J, Martinez C, Hamdi A, Mehta RS, Chemaly RF, Saunders IM, Bollard CM, Shpall EJ. General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation. Biol Blood Marrow Transplant 21(7):1284-90, 2015. e-Pub 2015. PMID: 25708219.
Konopleva M, Benton CB, Thall PF, Zeng Z, Shpall E, Ciurea S, Kebriaei P, Alousi A, Popat U, Anderlini P, Nieto Y, Parmar S, Qiao W, Chen J, Rondon G, McMullin B, Wang RY, Lu H, Schober W, Woodworth G, Gulbis A, Cool R, Andreeff M, Champlin R. Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation. Bone Marrow Transplant 50(7):939-46, 2015. e-Pub 2015. PMID: 25867648.
Beitinjaneh A, Saliba RM, Medeiros LJ, Turturro F, Rondon G, Korbling M, Fayad L, Fanale MA, Alousi AM, Anderlini P, Betul O, Popat UR, Pro B, Khouri IF. Comparison of Survival in Patients with T Cell Lymphoma after Autologous and Allogeneic Stem Cell Transplantation as a Frontline Strategy or in Relapsed Disease. Biol Blood Marrow Transplant 21(5):855-9, 2015. e-Pub 2015. PMID: 25652691.
Alousi AM, Brammer JE, Saliba RM, Andersson B, Popat U, Hosing C, Jones R, Shpall EJ, Khouri I, Qazilbash M, Nieto Y, Shah N, Ahmed S, Oran B, Al Atrash G, Ciurea S, Kebriaei P, Chen J, Rondon G, Champlin RE. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. Biol Blood Marrow Transplant 21(5):906-12, 2015. e-Pub 2015. PMID: 25667989.
Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, McNiece I, Oran B, Hosing C, Olson A, Parmar S, Shah N, Andreeff M, Kebriaei P, Kaur I, Yvon E, de Lima M, Cooper LJ, Tewari P, Champlin RE, Nieto Y, Andersson BS, Alousi A, Jones RB, Qazilbash MH, Bashir Q, Ciurea S, Ahmed S, Anderlini P, Bosque D, Bollard C, Molldrem JJ, Chen J, Rondon G, Thomas M, Miller L, Wolpe S, Simmons P, Robinson S, Zweidler-McKay PA, Shpall EJ. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood 125(19):2885-92, 2015. e-Pub 2015. PMID: 25778529.
Hobbs GS, Hamdi A, Hilden PD, Goldberg JD, Poon ML, Ledesma C, Devlin SM, Rondon G, Papadopoulos EB, Jakubowski AA, O'Reilly RJ, Champlin RE, Giralt S, Perales MA, Kebriaei P. Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts. Bone Marrow Transplant 50(4):493-8, 2015. e-Pub 2015. PMID: 25621808.
Kongtim P, Di Stasi A, Rondon G, Chen J, Adekola K, Popat U, Oran B, Kebriaei P, Andersson BS, Champlin RE, Ciurea SO. Can a female donor for a male recipient decrease the relapse rate for patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation?. Biol Blood Marrow Transplant 21(4):713-9, 2015. e-Pub 2015. PMID: 25540936.
Rathi NK, Tanner AR, Dinh A, Dong W, Feng L, Ensor J, Wallace SK, Haque SA, Rondon G, Price KJ, Popat U, Nates JL. Low-, medium- and high-dose steroids with or without aminocaproic acid in adult hematopoietic SCT patients with diffuse alveolar hemorrhage. Bone Marrow Transplant 50(3):420-6, 2015. e-Pub 2015. PMID: 25531284.
Walker GV, Shihadeh F, Kantarjian H, Allen P, Rondon G, Kebriaei P, O'Brien S, Kedir A, Said M, Grant JD, Thomas DA, Gidley PW, Arzu I, Pinnix C, Reed V, Dabaja BS. Comprehensive craniospinal radiation for controlling central nervous system leukemia. Int J Radiat Oncol Biol Phys 90(5):1119-25, 2014. e-Pub 2014. PMID: 25539370.
Di Stasi A, Milton DR, Poon LM, Hamdi A, Rondon G, Chen J, Pingali SR, Konopleva M, Kongtim P, Alousi A, Qazilbash MH, Ahmed S, Bashir Q, Al-Atrash G, Oran B, Hosing CM, Kebriaei P, Popat U, Shpall EJ, Lee DA, de Lima M, Rezvani K, Khouri IF, Champlin RE, Ciurea SO. Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigen-Matched Unrelated and Related Donors. Biol Blood Marrow Transplant 20(12):1975-81, 2014. e-Pub 2014. PMID: 25263628.
Hamdi A, Mawad R, Bassett R, di Stasi A, Ferro R, Afrough A, Ram R, Dabaja B, Rondon G, Champlin R, Sandmaier BM, Doney K, Bar M, Kebriaei P. Central Nervous System Relapse in Adults with Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 20(11):1767-71, 2014. e-Pub 2014. PMID: 25017763.
Oran B, Kongtim P, Popat U, de Lima M, Jabbour E, Lu X, Chen J, Rondon G, Kebriaei P, Ahmed S, Andersson B, Alousi A, Ciurea S, Shpall E, Champlin RE. Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation. Biol Blood Marrow Transplant 20(10):1618-25, 2014. e-Pub 2014. PMID: 24953017.
Khouri IF, Wei W, Korbling M, Turturro F, Ahmed S, Alousi A, Anderlini P, Ciurea S, Jabbour E, Oran B, Popat UR, Rondon G, Bassett RL, Gulbis A. BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD. Blood 124(14):2306-12, 2014. e-Pub 2014. PMID: 25145344.
Parmar S, de Lima M, Worth L, Petropoulos D, Lee D, Cooper L, Kongtim P, Alousi A, Hosing C, Popat U, Kebriaei P, McNiece I, Shpall E, Rondon G, Champlin R. Is there an expiration date for a cord blood unit in storage?. Bone Marrow Transplant 49(8):1109-12, 2014. e-Pub 2014. PMID: 24797184.
Zhou Y, Slack R, Jorgensen JL, Wang SA, Rondon G, de Lima M, Shpall E, Popat U, Ciurea S, Alousi A, Qazilbash M, Hosing C, O'Brien S, Thomas D, Kantarjian H, Medeiros LJ, Champlin RE, Kebriaei P. The Effect of Peritransplant Minimal Residual Disease in Adults With Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk 14(4):319-26, 2014. e-Pub 2014. PMID: 24548609.
Shah DP, Ghantoji SS, Ariza-Heredia EJ, Shah JN, El Taoum KK, Shah PK, Nesher L, Hosing C, Rondon G, Champlin RE, Chemaly RF. An Immunodeficiency Scoring Index to predict poor outcomes in hematopoietic cell transplant recipients with respiratory syncytial virus infections. Blood 123(21):3263-8, 2014. e-Pub 2014. PMID: 24700783.
Bayraktar UD, Shpall EJ, Liu P, Ciurea SO, Rondon G, de Lima M, Cardenas-Turanzas M, Price KJ, Champlin RE, Nates JL. Hematopoietic Cell Transplantation-Specific Comorbidity Index Predicts Inpatient Mortality and Survival in Patients Who Received Allogeneic Transplantation Admitted to the Intensive Care Unit. J Clin Oncol 31(33):4207-14, 2013. e-Pub 2013. PMID: 24127454.
Bashir Q, Khan H, Thall PF, Liu P, Shah N, Kebriaei P, Parmar S, Oran B, Ciurea S, Nieto Y, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Orlowski RZ, Shah JJ, De Lima M, Shpall E, Champlin R, Giralt S, Qazilbash MH. A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma. Biol Blood Marrow Transplant 19(10):1453-8, 2013. e-Pub 2013. PMID: 23872222.
Smith VR, Popat U, Ciurea S, Nieto Y, Anderlini P, Rondon G, Alousi A, Qazilbash M, Kebriaei P, Khouri I, de Lima M, Champlin R, Hosing C. Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization. Am J Hematol 88(9):754-7, 2013. e-Pub 2013. PMID: 23749720.
Wilhelm K, Chemaly R, Saliba R, Gulbis A, Saunders I, Cool R, Ferguson J, Westmoreland M, Rondon G, Kebriaei P. The impact of pre-transplant valganciclovir on early cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation. J Oncol Pharm Pract. e-Pub 2013. PMID: 24022408.
Pemmaraju N, Tanaka MF, Ravandi F, Lin H, Baladandayuthapani V, Rondon G, Giralt SA, Chen J, Pierce S, Cortes J, Kantarjian H, Champlin RE, De Lima M, Qazilbash MH. Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk 13(4):485-92, 2013. e-Pub 2013. PMID: 23769669.
Shah DP, Ghantoji SS, Shah JN, El Taoum KK, Jiang Y, Popat U, Hosing C, Rondon G, Tarrand JJ, Champlin RE, Chemaly RF. Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. J Antimicrob Chemother 68(8):1872-80, 2013. e-Pub 2013. PMID: 23572228.
Poon LM, Hamdi A, Saliba R, Rondon G, Ledesma C, Kendrick M, Qazilbash M, Hosing C, Jones RB, Popat UR, Nieto Y, Alousi A, Ciurea S, Shpall EJ, Champlin RE, Kebriaei P. Outcomes of adults with acute lymphoblastic leukemia (ALL) following relapse post allogeneic hematopoietic stem cell transplantation (HSCT). Biol Blood Marrow Transplant 19(7):1059-64, 2013. e-Pub 2013. PMID: 23644077.
Bayraktar UD, de Lima M, Saliba RM, Maloy M, Castro-Malaspina HR, Chen J, Rondon G, Chiattone A, Jakubowski AA, Boulad F, Kernan NA, O'Reilly RJ, Champlin RE, Giralt S, Andersson BS, Papadopoulos EB. Ex Vivo T Cell Depleted versus Unmodified Allografts in Patients with Acute Myeloid Leukemia in First Complete Remission. Biol Blood Marrow Transplant 19(6):898-903, 2013. e-Pub 2013. PMID: 23467126.
Poon LM, Bassett R, Rondon G, Hamdi A, Qazilbash M, Hosing C, Jones RB, Shpall EJ, Popat UR, Nieto Y, Worth LL, Cooper L, De Lima M, Champlin RE, Kebriaei P. Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia. Bone Marrow Transplant 48(5):666-70, 2013. e-Pub 2013. PMID: 23085830.
Hammerstrom AE, Howell J, Gulbis A, Rondon G, Champlin RE, Popat U. Tacrolimus-associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem cell transplantation. Am J Hematol 88(4):301-5, 2013. e-Pub 2013. PMID: 23460378.
Parmar S, Rondon G, de Lima M, Thall P, Bassett R, Anderlini P, Kebriaei P, Khouri I, Ganesan P, Champlin R, Giralt S. Dose intensification of Busulfan in the preparative regimen is associated with improved survival: A Phase I/II Controlled, Randomized Study. Biol Blood Marrow Transplant 19(3):474-80, 2013. e-Pub 2013. PMID: 23220013.
Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, Hosing C, Shpall EJ, Alousi A, Kebriaei P, Qazilbash M, Parmar S, Bashir Q, Shah N, Khouri I, Rondon G, Champlin R, Jones RB. Autologous Stem-Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome. Biol Blood Marrow Transplant 19(3):410-7, 2013. e-Pub 2013. PMID: 23128322.
Jabbour E, Mathisen MS, Garcia-Manero G, Champlin R, Popat U, Khouri I, Giralt S, Kadia T, Chen J, Pierce S, Koca E, Daver N, Tanaka M, Rondon G, Oran B, Parmar S, Kantarjian H, de Lima M. Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study. Am J Hematol 88(3):198-200, 2013. e-Pub 2013. PMID: 23345254.
Oran B, Popat U, Rondon G, Ravandi F, Garcia-Manero G, Abruzzo L, Andersson BS, Bashir Q, Chen J, Kebriaei P, Khouri IF, Koca E, Qazilbash MH, Champlin R, de Lima M. Significance of Persistent Cytogenetic Abnormalities on Myeloablative Allogeneic Stem Cell Transplantation in First Complete Remission. Biol Blood Marrow Transplant 19(2):214-20, 2013. e-Pub 2013. PMID: 22982533.
Cheng YC, Rondón G, Anderlini P, Khouri IF, Champlin RE, Ueno NT. Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation. J Cancer 4(8):679-85, 2013. e-Pub 2013. PMID: 24155780.
Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R, Wang SA, Konopleva M, Fernandez-Vina M, Montes N, Bosque D, Chen J, Rondon G, Alatrash G, Alousi A, Bashir Q, Korbling M, Qazilbash M, Parmar S, Shpall E, Nieto Y, Hosing C, Kebriaei P, Khouri I, Popat U, de Lima M, Champlin RE. Improved Early Outcomes Using a T-cell Replete Graft Compared with T-cell Depleted Haploidentical Hematopoietic Stem-Cell Transplantation. Biol Blood Marrow Transplant 18(12):1835-44, 2012. e-Pub 2012. PMID: 22796535.
de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, McMannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, Shah N, Oran B, Cooper LJ, Worth L, Qazilbash MH, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons PJ, Shpall EJ. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 367(24):2305-15, 2012. e-Pub 2012. PMID: 23234514.
Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P, Shpall EJ, Bassett R, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Frazier E, Gulbis A, Chancoco C, Bashir Q, Ciurea S, Khouri I, Parmar S, Shah N, Worth L, Rondon G, Champlin R, Jones RB. High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphoid Malignancies. Biol Blood Marrow Transplant 18(11):1677-86, 2012. e-Pub 2012. PMID: 22643322.
Beitinjaneh AM, Saliba R, Bashir Q, Shah N, Parmar S, Hosing C, Popat U, Anderlini P, Dinh Y, Qureshi S, Rondon G, Champlin RE, Giralt SA, Qazilbash MH. Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant. Leuk Lymphoma 53(8):1525-9, 2012. e-Pub 2012. PMID: 22242817.
Ciurea SO, Saliba RM, Hamerschlak N, Karduss Aurueta AJ, Bassett R, Fernandez-Vina M, Petropoulos D, Worth LL, Chan KW, Couriel DR, Rondon G, Sharma M, Qazilbash M, Jones RB, Kebriaei P, McMannis J, Hosing CM, Nieto Y, Champlin RE, Shpall EJ, de Lima M. Fludarabine, Melphalan, Thiotepa and ATG Conditioning for Unrelated Cord Blood Transplantation. Leuk Lymphoma 53(5):901-6, 2012. e-Pub 2012. PMID: 21988645.
Kebriaei P, Saliba R, Rondon G, Chiattone A, Luthra R, Anderlini P, Andersson B, Shpall E, Popat U, Jones R, Worth L, Ravandi F, Thomas D, O'Brien S, Kantarjian H, de Lima M, Giralt S, Champlin R. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes. Biol Blood Marrow Transplant 18(4):584-92, 2012. e-Pub 2012. PMID: 21867666.
Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Thomas SK, Shah JJ, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol 87(3):272-6, 2012. e-Pub 2012. PMID: 22231283.
Kebriaei P, Huls H, Jena B, Munsell M, Jackson R, Lee DA, Hackett PB, Rondon G, Shpall E, Champlin RE, Cooper LJ. Infusing CD19-Directed T Cells to Augment Disease Control in Patients Undergoing Autologous Hematopoietic Stem-Cell Transplantation for Advanced B-Lymphoid Malignancies. Hum Gene Ther. e-Pub 2012. PMID: 22107246.
Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Feasibility of autologous hematopoietic stem cell transplant in patients aged 70 years with multiple myeloma. Leuk Lymphoma 53(1):118-22, 2012. e-Pub 2012. PMID: 21780997.
Saliba RM, Couriel DR, Giralt S, Rondon G, Okoroji GJ, Rashid A, Champlin RE, Alousi AM. Prognostic value of response after upfront therapy for acute GVHD. Bone Marrow Transplant 47(1):125-31, 2012. e-Pub 2012. PMID: 21383686.
Alatrash G, Pelosini M, Saliba RM, Koca E, Rondon G, Andersson BS, Chiattone A, Zhang W, Giralt SA, Cernosek AM, Kebriaei P, Alousi AM, Popat UR, Hosing C, Khouri IF, Champlin RE, de Lima MJ. Platelet recovery before allogeneic stem cell transplantation predicts posttransplantation outcomes in patients with acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 17(12):1841-5, 2011. e-Pub 2011. PMID: 21684343.
Shah N, Ahmed F, Bashir Q, Qureshi S, Dinh Y, Rondon G, Wen S, Thall P, Khan H, Giralt S, Champlin R, Qazilbash MH. Durable remission with salvage second autotransplants in patients with multiple myeloma. Cancer. e-Pub 2011. PMID: 22086552.
Ciurea SO, Thall PF, Wang X, Wang SA, Hu Y, Cano P, Aung F, Rondon G, Molldrem JJ, Korbling M, Shpall EJ, de Lima M, Champlin RE, Fernandez-Vina M. Donor-specific anti-HLA antibodies and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood 118(22):5957-64, 2011. e-Pub 2011. PMID: 21967975.
Khan H, Oberoi S, Mahvash A, Sharma M, Rondon G, Alousi A, Shpall EJ, Kontoyiannis DP, Champlin RE, Ciurea SO. Reversible Ureteral Obstruction due to Polyomavirus Infection after Percutaneous Nephrostomy Catheter Placement. Biol Blood Marrow Transplant 17(10):1551-5, 2011. e-Pub 2011. PMID: 21396475.
Alatrash G, de Lima M, Hamerschlak N, Pelosini M, Wang X, Xiao L, Kerbauy F, Chiattone A, Rondon G, Qazilbash MH, Giralt SA, de Padua Silva L, Hosing C, Kebriaei P, Zhang W, Nieto Y, Saliba RM, Champlin RE, Andersson BS. Myeloablative Reduced-Toxicity i.v. Busulfan-Fludarabine and Allogeneic Hematopoietic Stem Cell Transplant for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome in the Sixth through Eighth Decades of Life. Biol Blood Marrow Transplant 17(10):1490-6, 2011. e-Pub 2011. PMID: 21338705.
Jabbour E, Cortes J, Santos FP, Jones D, O'Brien S, Rondon G, Popat U, Giralt S, Kebriaei P, Jones RB, Kantarjian H, Champlin R, de Lima M. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood 117(13):3641-7, 2011. e-Pub 2011. PMID: 21156844.
Westin JR, Saliba RM, De Lima M, Alousi A, Hosing C, Qazilbash MH, Khouri IF, Shpall EJ, Anderlini P, Rondon G, Andersson BS, Champlin R, Couriel DR. Steroid-Refractory Acute GVHD: Predictors and Outcomes. Adv Hematol 2011:601953, 2011. e-Pub 2011. PMID: 22110505.
Ciurea SO, Mulanovich V, Jiang Y, Bassett R, Rondon G, McMannis J, de Lima M, Shpall EJ, Champlin RE. Lymphocyte Recovery Predicts Outcomes in Cord Blood and T-Cell Depleted Haploidentical Stem Cell Transplantation. Biol Blood Marrow Transplant. e-Pub 2010. PMID: 21126598.
Andersson BS, Valdez BC, de Lima M, Wang X, Thall PF, Worth LL, Popat U, Madden T, Hosing C, Alousi A, Rondon G, Kebriaei P, Shpall EJ, Jones RB, Champlin RE. Clofarabine±Fludarabine with Once Daily IV Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and MDS. Biol Blood Marrow Transplant. e-Pub 2010. PMID: 20946966.
Ciurea SO, Saliba RM, Rondon G, Patah PA, Aung F, Cano P, Andersson BS, Kebriaei P, Popat U, Fernandez-Vina M, Champlin RE, de Lima M. Outcomes of Patients with Myeloid Malignancies Treated with Allogeneic Hematopoietic Stem Cell Transplantation from Matched Unrelated Donors Compared with One Human Leukocyte Antigen Mismatched Related Donors Using HLA Typing at 10 Loci. Biol Blood Marrow Transplant. e-Pub 2010. PMID: 20969970.
Velev N, Cortes J, Champlin R, Jones D, Rondon G, Giralt S, Borthakur G, Kantarjian HM, De Lima M. Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. Cancer 116(15):3631-7, 2010. e-Pub 2010. PMID: 20564073.
Ramos CA, Saliba RM, de Pádua Silva L, Khorshid O, Shpall EJ, Giralt S, Patah PA, Hosing CM, Popat UR, Rondon G, Nieto Y, Champlin RE, de Lima M. Resolved Hepatitis B Virus Infection Is Not Associated with Worse Outcome after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 16(5):686-694, 2010. e-Pub 2010. PMID: 20056165.
Ciurea SO, Saliba R, Rondon G, Pesoa S, Cano P, Fernandez-Vina M, Qureshi S, Worth LL, McMannis J, Kebriaei P, Jones RB, Korbling M, Qazilbash M, Shpall EJ, Giralt S, de Lima M, Champlin RE, Gajewski J. Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transplant 45(3):429-36, 2010. e-Pub 2010. PMID: 19668237.
Cheng YC, Rondón G, Sanchez LF, McMannis JD, Couriel DR, de Lima MJ, Hosing C, Khouri IF, Giralt SA, Champlin RE, Ueno NT. Interleukin-2 and granulocyte-macrophage-colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Int J Hematol 90(5):627-34, 2009. e-Pub 2009. PMID: 19998065.
Nakayama K, Liu P, Detry M, Schover LR, Milbourne A, Neumann J, Rondon G, Thewes B, Champlin RE, Ueno NT. Receiving information on fertility-and menopause-related treatment effects among women who undergo hematopoietic stem cell transplantation: changes in perceived importance over time. Biol Blood Marrow Transplant 15(11):1465-74, 2009. e-Pub 2009. PMID: 19822307.
Parmar S, Del Lima M, Zou Y, Patah PA, Liu P, Cano P, Rondon G, Pesoa S, de Padua Silva L, Qazilbash MH, Hosing C, Popat U, Kebriaei P, Shpall EJ, Giralt S, Champlin RE, Stastny P, Fernandez-Vina M. Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. Blood 114(14):2884-7, 2009. e-Pub 2009. PMID: 19654407.
de Souza JA, Saliba RM, Patah P, Rondon G, Ribeiro R, de Padua Silva L, Qazilbash MH, Hosing C, Popat U, Efebera Y, Champlin RE, de Lima M. Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 15(9):1094-9, 2009. e-Pub 2009. PMID: 19660722.
de Souza JA, Davis ML, Rondon G, Cheng YC, Jones RB, Champlin RE, Ueno NT. Prolonged disease control by nonmyeloablative allogeneic transplantation for metastatic breast cancer. Bone Marrow Transplant 44(2):81-7, 2009. e-Pub 2009. PMID: 19448681.
Saliba RM, Komanduri KV, Giralt S, de Souza J, Patah P, Oran B, Couriel D, Rondon G, Champlin RE, de Lima M. Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML. Bone Marrow Transplant 43(9):685-92, 2009. e-Pub 2009. PMID: 19011667.
van Besien K, Kunavakkam R, Rondon G, De Lima M, Artz A, Oran B, Giralt S. Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant 15(5):610-7, 2009. e-Pub 2009. PMID: 19361753.
Tam CS, Bassett R, Ledesma C, Korbling M, Alousi A, Hosing C, Kebraei P, Harrell R, Rondon G, Giralt SA, Anderlini P, Popat U, Pro B, Samuels B, Hagemeister F, Medeiros LJ, Champlin RE, Khouri IF. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 113(18):4144-52, 2009. e-Pub 2009. PMID: 19168784.
Ramos CA, Saliba RM, de Pádua L, Khorshid O, Shpall EJ, Giralt S, Patah PA, Hosing CM, Popat UR, Rondon G, Khouri IF, Nieto YL, Champlin RE, de Lima M. Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Haematologica 94(2):249-57, 2009. e-Pub 2009. PMID: 19144658.
Efebera YA, Thandi RS, Saliba RM, Popat U, De Lima M, Alousi A, Hosing C, Rondon G, Champlin R, Giralt S. The Impact of Pre-Stem Cell Transplant Ferritin Level on Late Transplant Complications: An Analysis to Determine the Potential Role of Iron Overload on Late Transplant Outcomes. Internet J Hematol 7(1), 2009. e-Pub 2009. PMID: 25356072.
Rondón G, Saliba RM, Khouri I, Giralt S, Chan K, Jabbour E, McMannis J, Champlin R, Shpall E. Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis. Biol Blood Marrow Transplant 14(8):859-66, 2008. e-Pub 2008. PMID: 18640568.
Jabbour E, Rondon G, Anderlini P, Giralt SA, Couriel DR, Champlin RE, Khouri IF. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation. Bone Marrow Transplant 40(5):431-5, 2007. e-Pub 2007. PMID: 17603511.
Patah PA, Parmar S, McMannis J, Sadeghi T, Karandish S, Rondon G, Tarrand J, Champlin R, de Lima M, Shpall EJ. Microbial contamination of hematopoietic progenitor cell products: clinical outcome. Bone Marrow Transplant 40(4):365-8, 2007. e-Pub 2007. PMID: 17572714.
Ueno NT, Konoplev S, Buchholz TA, Smith T, Rondon G, Anderlini P, Giralt SA, Gajewski JL, Donato ML, Cristofanilli M, Champlin RE. High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy. Bone Marrow Transplant 37:929-35, 2006. e-Pub 2006. PMID: 16565737.
Cheng YC, Saliba RM, Rondon G, Giralt SA, Lu KH, Bodurka DC, Gershenson DM, Champlin RE, Ueno NT. Low prevalence of premature ovarian failure in women given reduced-intensity conditioning regimens for hematopoietic stem-cell transplantation. Haematologica 90(12):1725-6, 2005. e-Pub 2005. PMID: 16330461.
Cheng YC, Rondon G, Yang Y, Smith TL, Gajewski JL, Donato ML, Shpall EJ, Jones R, Hortobagyi GN, Champlin RE, Ueno NT. The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy. Biol Blood Marrow Transplant 10(11):794-804, 2004. e-Pub 2004. PMID: 15505610.
Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, de Lima M, Hosing C, Anderlini P, Donato M, Cleary K, Gajewski J, Neumann J, Ippoliti C, Rondon G, Cohen A, Champlin R. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 10(3):178-85, 2004. e-Pub 2004. PMID: 14993883.
Ueno NT, Cheng YC, Rondon G, Tannir NM, Gajewski JL, Couriel DR, Hosing C, de Lima MJ, Anderlini P, Khouri IF, Booser DJ, Hortobagyi GN, Pagliaro LC, Jonasch E, Giralt SA, Champlin RE. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 102(10):3829-36, 2003. e-Pub 2003. PMID: 12881308.
Wong R, Rondon G, Saliba RM, Shannon VR, Giralt SA, Champlin RE, Ueno NT. Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer. Bone Marrow Transplant 31(12):1157-63, 2003. e-Pub 2003. PMID: 12796796.
Montemurro F, Rondon G, Munsell M, Smith TL, Donato ML, Gajewski JL, Rahman ZU, Buzdar AU, Champlin RE, Ueno NT. Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection. Biol Blood Marrow Transplant 9(5):330-40, 2003. e-Pub 2003. PMID: 12766883.
Montemurro F, Rondon G, Ueno NT, Munsell M, Gajewski JL, Champlin RE. Factors affecting progression-free survival in hormone-dependent metastatic breast cancer patients receiving high-dose chemotherapy and hematopoietic progenitor cell transplantation: role of maintenance endocrine therapy. Bone Marrow Transplant 29(10):861-6, 2002. e-Pub 2002. PMID: 12058236.
Korbling M, Katz RL, Khanna A, Ruifrok AC, Rondon G, Albitar M, Champlin RE, Estrov Z. Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells. N Engl J Med 346(10):738-46, 2002. e-Pub 2002. PMID: 11882729.
Gajewski JL, Rondon G, Donato ML, Anderlini P, Korbling M, Ippoliti C, Benyunes M, Miller LL, LaTemple D, Jones D, Ashby M, Hellmann S, Durett A, Lauppe J, Geisler D, Khouri IF, Giralt SA, Andersson B, Ueno NT, Champlin R. Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization. Biol Blood Marrow Transplant 8(10):550-6, 2002. e-Pub 2002. PMID: 12434950.
Kim YS, Konoplev SN, Montemurro F, Hoy E, Smith TL, Rondon G, Champlin RE, Sahin AA, Ueno NT. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation. Clin Cancer Res 7(12):4008-12, 2001. e-Pub 2001. PMID: 11751494.
Hortobagyi GN, Buzdar AU, Theriault RL, Valero V, Frye D, Booser DJ, Holmes FA, Giralt S, Khouri I, Andersson B, Gajewski JL, Rondon G, Smith TL, Singletary SE, Ames FC, Sneige N, Strom EA, McNeese MD, Deisseroth AB, Champlin RE. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst 92(3):225-33, 2000. e-Pub 2000. PMID: 10655439.
Braunschweig I, Mirza NQ, Rondon G, Lauppe J, Mehra R, Gajewski J, Korbling M, Huh YO, Geisler D, Gee AP, Champlin R, Przepiorka D. High CD34 cell doses do not worsen regimen-related toxicity or early mortality after autologous blood stem cell transplantation for breast cancer. Cytotherapy 2(2):105-10, 2000. e-Pub 2000. PMID: 12042047.
Bernstein SH, Nademanee AP, Vose JM, Tricot G, Fay JW, Negrin RS, DiPersio J, Rondon G, Champlin R, Barnett MJ, Cornetta K, Herzig GP, Vaughan W, Geils G, Jr, Keating A, Messner H, Wolff SN, Miller KB, Linker C, Cairo M, Hellmann S, Ashby M, Stryker S, Nash RA. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. Blood 91(9):3509-17, 1998. e-Pub 1998. PMID: 9558412.
Ueno NT, Rondon G, Mirza NQ, Geisler DK, Anderlini P, Giralt SA, Andersson BS, Claxton DF, Gajewski JL, Khouri IF, Korbling M, Mehra RC, Przepiorka D, Rahman Z, Samuels BI, van Besien K, Hortobagyi GN, Champlin RE. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 16(3):986-93, 1998. e-Pub 1998. PMID: 9508181.
Rahman Z, Champlin R, Rondon G, Frye D, Valero V, Mehra R, Hortobagyi G. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer. Semin Oncol 24(8888):S17-77-S17-80, 1997. e-Pub 1997. PMID: 9374100.
Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, Korbling M, Keating M, Kantarjian H, Champlin R. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89(12):4531-6, 1997. e-Pub 1997. PMID: 9192777.
Rondon G, Giralt S, Pereira M, Van Besien K, Mehra R, Champlin R, Andreeff M. Analysis of chimerism following allogeneic bone marrow transplantation by fluorescent-in-situ hybridization. Leuk Lymphoma 25(5-6):463-7, 1997. e-Pub 1997. PMID: 9250816.
van Besien KW, de Lima M, Giralt SA, Moore DF, Jr, Khouri IF, Rondon G, Mehra R, Andersson BS, Dyer C, Cleary K, Przepiorka D, Gajewski JL, Champlin RE. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant 19(10):977-82, 1997. e-Pub 1997. PMID: 9169641.
Johansen MJ, Madden T, Mehra RC, Wood JG, Rondon G, Browne V, Newman RA, Champlin RE. Phase I pharmacokinetic study of multicycle high-dose carboplatin followed by peripheral-blood stem-cell infusion in patients with cancer. J Clin Oncol 15(4):1481-91, 1997. e-Pub 1997. PMID: 9193344.
Rondon G, Giralt S, Huh Y, Khouri I, Andersson B, Andreeff M, Champlin R. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 18(3):669-72, 1996. e-Pub 1996. PMID: 8879640.
Giralt S, Hester J, Huh Y, Hirsch-Ginsberg C, Rondon G, Seong D, Lee M, Gajewski J, Van Besien K, Khouri I, Mehra R, Przepiorka D, Korbling M, Talpaz M, Kantarjian H, Fischer H, Deisseroth A, Champlin R. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 86(11):4337-43, 1995. e-Pub 1995. PMID: 7492795.
Hester JP, Rondón G, Huh YO, Lauppe J, Champlin RE, and Deisseroth AB. Principles of Bone Marrow Processing and Progenitor Cell/Mononuclear Cell Concentrate Collection in a Continuous Flow Blood Cell Separation System. Journal of Hematotherapy 4(8888):299-306, 1995. e-Pub 1995.
Giralt S, O’Brien S, Talpaz M, van Besien K, Chan K, Rondón G, Andersson B, Mehra R, Khouri I, Estey E, and Champlin R. Alpha Interferon and Interleukin-2 as Treatment for Leukemia Relapse After Allogeneic Bone Marrow Transplantation. Cytokines and Molecular Therapy 1/2(8888):115-122, 1995. e-Pub 1995.
Rondón G, Murillo J, Guzmán M, Istúriz R, Otero C, López G, Flores A. Actividad comparativa in vitro de norfloxacina, betalactamicos y aminoglicosidos contra cepas de enterobacterias y Pseudomonas Aeruginosa. Archivos Venezolanos de Farmacología y Terapéutica médica 4(8888):417-420, 1985. e-Pub 1985.

Review Articles

Damron EP, Qazilbash MH, Fang PQ, Wu SY, Dabaja BS, Rondon G, Hosing C, Champlin RE, Bashir Q, Shpall EJ, Knafl MK, Lee HC, Manasanch EE, Patel K, Thomas SK, Orlowski RZ, Weber DM, Pinnix CC, Gunther JR. Radiation Therapy Can Be Safely Incorporated into Pretransplantation Treatment Regimens for Patients with Multiple Myeloma. Transplant Cell Ther 29(1):37.e1-37.e7, 2023. e-Pub 2023. PMID: 37753818.
Champlin R, de Lima M, Kebriaei P, Rondon G, Fisher T, Jabbour E, Cortés JE, Kantarjian H, Anderlini P, Alousi A, Hosing C, Shpall E, Popat U, Qazilbash M, Andersson B, Giralt S. Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. Clin Lymphoma Myeloma 9 Suppl 3:S261-5, 2009. e-Pub 2009. PMID: 19778850.
Ueno NT, Anagnostopoulos A, Rondon G, Champlin RE, Mikhailova N, Pankratova OS, Zoubarovskaya LS, Semenova EV, Afanasyev BV, O'Brien S, Andreeff M, Zaritskey AY. Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. Br J Haematol 119(1):131-4, 2002. e-Pub 2002. PMID: 12358917.
Montemurro F, Ueno NT, Rondon G, Aglietta M, Champlin RE. High-dose chemotherapy with hematopoietic stem-cell transplantation for breast cancer: current status, future trends. Clin Breast Cancer 1(3):197-209; discussion 210, 2000. e-Pub 2000. PMID: 11899644.
Hester J, Bojko P, Rondon G, Champlin R. Integration of biological, procedural, apheresis principles of peripheral blood stem cell transplantation programs. Transfus Sci 17(4):585-90, 1996. e-Pub 1996. PMID: 10168556.

Abstracts

Fingrut WB, Codrington K, Hunter L, Garcia R, Martinez C, Rondon G, Milton DR, Flowers CR, Shpall EJ. Prospective Observational Cohort Study to Collect Granular Social Determinants of Health Data for Transplant and Cellular Therapy Candidates and Recipients. ASH 2024, 2024. e-Pub 2024.
Arani N, Ratanasrimetha P, Lin H, Mamlouk O, Tchakarov A, Rondon G, Shpall E, Abudayyeh A. Transplant-Associated Renal Thrombotic Microangiopathy after Allogeneic SCT, 2024. e-Pub 2024.
Subramanian N, Klein K, Guffey D, Kebriaei P, Rondon G, Shpall EJ, Jin J, Young E, Li A, Rojas Hernandez CM. Clinical Factors Associated with Catheter-Related VTE in Patients Undergoing Hematopoietic Cell Transplantation. Blood, 2023. e-Pub 2023.
Bashir Q, Thall P, Sui D, Kawedia J, Knape C, Delgado R, Schindler JL, Popat UR, Kebriaei P, Hosing C, Khouri IF, Nieto Y, Oran B, Srour SA, Saini NY, Olson AL, Ahmed S, Alatrash G, Rondon G, Lee H, Thomas SK, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Phase 1/2 Trial to Jointly Optimize Dose and Administration Schedule of Evomela in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. Blood, 2023. e-Pub 2023.
Saliba RM, Marcoux C, Alousi A, Rondon G, Chen J, Daher M, Champlin RE, Rezvani K, Shpall EJ, Mehta RS. The Impact of Post-Transplant Cyclophosphamide (PTCy) with or without MMF in the Prevention of De Novo and Progressive / Relapsing Chronic Graft-Versus-Host Disease after HLA-Matched Donor Transplant. Blood, 2023. e-Pub 2023.
Qazilbash MH, Khan HN, Milton DR, Pasvolsky O, Tanner MR, Popat UR, Kebriaei P, Hosing C, Khouri IF, Rezvani K, Nieto Y, Oran B, Srour SA, Saini NY, Olson AL, Ahmed S, Alatrash G, Rondon G, Konopleva MY, Champlin RE, Shpall EJ, Bashir Q, Pemmaraju N. Patient Characteristics and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood, 2023. e-Pub 2023.
Khouri IF, Alzahrani K, Gulbis A, Sasaki K, Jain N, Short NJ, Kadia TM, Daher M, Rafei H, Im JS, Marin D, Olson AL, Popat UR, Qazilbash MH, Ramdial J, Rondon G, Srour SA, Kebriaei P, Shpall EJ, Kantarjian HM, Champlin RE, Jabbour E. Addition of Inotuzumab Ozogamicin to the Conditioning Regimen of Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed CD22 (+) Lymphoid Malignancies: Long-Term Survival Results. Blood, 2023. e-Pub 2023.
Marcoux C, Saliba RM, Wallis W, Khazal S, Ragoonanan D, Rondon G, Tewari P, Popat UR, Oran B, Olson AL, Bashir Q, Qazilbash MH, Alousi A, Hosing C, Nieto Y, Alatrash G, Marin D, Rezvani K, Khouri IF, Srour SA, Champlin RE, Shpall EJ, Kebriaei P. Incidence and Risk Factors of Veno-Occlusive Disease Are Different in Younger Versus Older Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2023. e-Pub 2023.
Rahman ZA, Koller PB, Othman T, Saliba RM, Moreno Vanegas YA, Mohty R, Ledesma C, Rondon G, Jain N, Jabbour E, Pullarkat V, Alkhateeb H, Kantarjian HM, Greipp P, Nakamura R, Kharfan-Dabaja MA, Champlin RE, Forman SJ, Shpall EJ, Litzow MR, Foran JM, Aldoss I, Kebriaei P. A Multicenter Analysis of Allogeneic Transplant Outcomes in Patients with Philadelphia-like (Ph-like) Acute Lymphoblastic Leukemia (ALL). Blood, 2023. e-Pub 2023.
Pasvolsky O, Shimony S, Saliba RM, Ledesma C, Rondon G, Tewari P, Ragoonanan D, Short NJ, Jabbour E, Gooptu M, Ho VT, Soiffer RJ, Antin J, Koreth J, Cutler C, Paolino J, Duncan C, Lehmann LE, DeAngelo DJ, Kantarjian HM, Champlin RE, Shpall EJ, Luskin MR, Kebriaei P. Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults with Acute Lymphoblastic Leukemia – Retrospective Dual-Center Study. Blood, 2023. e-Pub 2023.
Mehta RS, Saliba RM, Alousi AM, Alatrash G, Bashir Q, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Rondon G, Srour SA, Rezvani K, Champlin RE, Shpall EJ, Cao K. HLA B-Leader Mismatch Is Associated with Poor Outcomes in NIMA/NIPA Mismatched Haploidentical Sibling Donor HCT. Blood 140(Supplement 1):4880-4881, 2022. e-Pub 2022.
Pasvolsky O, Saliba RM, Popat UR, Alousi AM, Mehta RS, Yeh J, Alatrash G, Masood A, Ramdial JL, Rondon G, Kebriaei P, Champlin RE, Shpall EJ, Oran B. Efficacy of Azacitidine Post-Transplant Maintenance for FLT3-Negative Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood 140(Supplement 1):10550-10551, 2022. e-Pub 2022.
Mehta RS, Saliba RM, Alousi AM, Alatrash G, Bashir Q, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Rondon G, Srour SA, Rezvani K, Champlin RE, Shpall EJ, Cao K. Son Vs Daughter Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis. Blood 140(Supplement 1):7649-7650, 2022. e-Pub 2022.
Tang K, Khwaja R, Feng L, Strati P, Steiner RE, Nair R, Flowers CR, Saini N, Ramdial JL, Srour SA, Champlin RE, Rondon G, Torres J, Kebriaei P, Nastoupil LJ, Mistry H, Shpall EJ, Nieto Y, Westin J, Neelapu SS, Ahmed S. Comorbidities Associated with Early Mortality after CD19 CAR-T Cell Therapy. Blood 140(Supplement 1):4684-4685, 2022. e-Pub 2022.
Mehta RS, Saliba RM, Alousi AM, Alatrash G, Bashir Q, Kebriaei P, Khouri IF, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Rondon G, Srour SA, Rezvani K, Champlin RE, Shpall EJ, Cao K. Mother Vs Father Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis. Blood 140(Supplement 1):10530-10531, 2022. e-Pub 2022.
Ozcan G, Popat UR, Kebriaei P, Alousi AM, Alatrash G, Bashir Q, Mehta RS, Ramdial JL, Rondon G, Shpall EJ, Champlin RE, Oran B. Transplant Outcomes for TP53 AML and MDS in a Contemporary Era. Blood 140(Supplement 1):10620-10621, 2022. e-Pub 2022.
Saliba RM, Greenbaum U, Ma Q, Srour SA, Rondon G, Shpall EJ, Cao K, Champlin RE, Zou J. Mismatch in Sirpα, a Regulatory Protein in Innate Immunity, Is Associated with Outcomes of Allogeneic Stem Cell Transplantation for Lymphoid Malignancies. Blood 138(Supplement 1), 2021. e-Pub 2021.
Ramdial JL, Saliba RM, Alousi AM, Rondon G, Chen J, Ledesma C, Shpall EJ, Chemaly R, Champlin RE. Allogeneic and Autologous Hematopoietic Transplants Can be Safely Performed after COVID-19 Infections. Blood 138(Supplement 1), 2021. e-Pub 2021.
Li A, Martens KL, Nguyen D, Rondon G, Amos CI, Lee SJ, Basom R, Davis C, Garcia DA, Champlin RE, Shpall EJ, Rojas Hernandez CM, Kebriaei P. Internal and External Validation of the High-2-Low Model: A Predictive Score for Venous Thromboembolism after Allogeneic Transplant 138(Supplement 1), 2021. e-Pub 2021.
Al-Juhaishi T, Malek AE, Milton DR, Ramdial JL, Daher M, Olson AL, Srour SA, Alatrash G, Oran B, Mehta RS, Khouri IF, Bashir Q, Shah N, Ciurea SO, Rondon G, Maadani F, Hosing C, Marin D, Kebriaei P, Rezvani K, Nieto Y, Anderlini P, Alousi AM, Qazilbash MH, Popat UR, Champlin RE, Shpall EJ, Mulanovich V, Ahmed S. Incidence and Outcomes of Toxoplasma Reactivation in Patients with Hematologic Diseases after Allogeneic Hematopoietic Stem Cell Transplantation. Blood 138(Supplement 1), 2021. e-Pub 2021.
Srour SA, Milton DR, Bashir Q, Mehta RS, Saini N, Ciurea SO, Popat UR, Khouri IF, Kebriaei P, Delgado R, Rondon G, Manasanch E, Patel K, Lee HC, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Long-Term Survival for Myeloma after Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 26(3 Supplement):S238-S239, 2020. e-Pub 2020.
Popat UR, Saliba RM, Szewczyk N, Lindsay R, Rivera Z, Ferguson J, Fontillas RC, Adekoya L, Gale H, Lee CA, Cao L, Sullivan HB, Chen J, Rondon G, McMullin B, Shigle TL, Whited LK, Gulbis AM, Soones TN, Ngo-Huang A, Champlin RE. Enhanced Recovery Program in Older Patients Undergoing Allogeneic Stem Cell Transplantation (ER-SCT): First Year Outcomes. Biology of Blood and Marrow Transplantation 26(3 Supplement):S49-S50, 2020. e-Pub 2020.
Yeh J, Whited LK, Saliba RM, Rondon G, Popat UR. Cardiac Toxicities after HLA-Matched Allogeneic Hematopoietic Cell Transplantation (Allo-HCT): Post-Transplant Cyclophosphamide (PTCy) Is Not Associated with Higher Incidence of Cardiotoxicity. Biology of Blood and Marrow Transplantation 26(3 Supplement):S393-S394, 2020. e-Pub 2020.
Thall P, Milton DR, Kawedia JD, Kebriaei P, Patel K, Andersson BS, Nieto Y, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing CM, Popat UR, Oran B, Ciurea SO, Lin P, Weber D, Thomas S, Lee HC, Manasanch E, Orlowski RZ, Shpall EJ, Williams L, Champlin RE, Qazilbash MH. Conditioning with Busulfan Plus Melphalan (Bu-Mel) Results in More Prolonged Progression-Free Survival (PFS) Versus Melphalan (Mel) Alone before Autologous Stem Cell Transplantation (auto-HCT) in Patients with High-Risk Multiple Myeloma (MM): Long-Term Results of a Randomized, Phase 3 Trial. Biology of Blood and Marrow Transplantation 26(3 Supplement):S241-S242, 2020. e-Pub 2020.
Srour SA, Nieto Y, Iyer SP, Miranda RN, Maadani F, Rondon G, Saini N, Strati P, Daher M, Nair R, Dabaja BS, Popat UR, Qazilbash MH, Shpall EJ, Flowers C, Champlin RE, Hosing C, Khouri IF. Autologous Stem Cell Transplantation for Angioimmunoblastic T-Cell Lymphoma. Blood, 2020. e-Pub 2020.
Mukherjee A, Milton DR, Jabbour E, Daver N, Gulbis A, Ledesma C, Konopleva M, DiNardo CD, Ravandi F, Kadia TM, Alatrash G, Alousi AM, Daher M, Marin D, Olson AL, Oran B, Kebriaei P, Saini N, Srour SA, Popat UR, Im JS, Mehta R, Rondon G, Kantarjian HM, Champlin RE, Khouri IF. Risk of Gvhd and Survival in Patients with Acute Leukemia Who Were Bridged to Allogeneic Stem Cell Transplantation (alloSCT) with Venetoclax- Based Therapy. Blood, 2020. e-Pub 2020.
Khouri IF, Gruschkus SK, Gulbis A, Ledesma C, Jain N, Kadia TM, Pemmaraju N, Anderlini P, Bashir Q, Daher M, Kebriaei P, Marin D, Mehta R, Popat UR, Saini N, Srour SA, Im JS, Fayad L, Nair R, Iyer SP, Strati P, Samaniego F, Nastoupil LJ, Flowers C, Rondon G, Kantarjian HM, Champlin RE, Jabbour E. Nonmyeloablative Allogeneic Stem Cell Transplantation with or without Inotuzumab Ozogamicin for Lymphoid Malignancies. Blood, 2020. e-Pub 2020.
Khouri IF, Gruschkus SK, Ledesma C, Anderlini P, Bashir Q, Daher M, Iyer SP, Marin D, Mehta R, Olson AL, Popat UR, Samaniego F, Qazilbash MH, Im JS, Rondon G, Champlin RE, Gulbis A, Young KH. Autologous Vs. Allogeneic Stem Cell Transplantation in Double-Expressor Lymphoma. Blood, 2020. e-Pub 2020.
Srour SA, Bashir Q, Milton DR, Nieto Y, Mehta RS, Saini N, Delgado R, Rondon G, Hosing C, Ciurea SO, Daher M, Popat UR, Khouri IF, Kebriaei P, Manasanch EE, Kaufman GP, Patel KK, Shpall EJ, Lee HC, Orlowski RZ, Champlin RE, Qazilbash MH. Survival Trends in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplantation. Blood, 2020. e-Pub 2020.
Nieto Y, Gruschkus SK, Jones RB, Valdez BC, Timmons M, Hosing C, Anderlini P, Kebriaei P, Popat UR, Qazilbash MH, Alousi AM, Srour SA, Saini N, Ramdial J, Im JS, Shpall EJ, Rezvani K, Gulbis A, Shigle TL, Mahadeo KM, Khazal S, Khouri IF, Dabaja BS, Pinnix CC, Gunther JR, Lee H, Ahmed S, Steiner RE, Iyer SP, Nair R, Parmar S, Cuglievan B, Maadani F, Rondon G, Champlin RE, Andersson BS. Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience. Blood, 2020. e-Pub 2020.
Mehta RS, Saliba RM, Jan A, Shigle TL, Wang E, Rondon G, Nieto Y, Ciurea S, Oran B, Im JS, Olson AL, Marin D, Qazilbash MH, Khouri IF, Anderlini P, Rezvani K, Popat UR, Kebriaei P, Shpall EJ, Champlin RE, Alousi AM. Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft Versus Host Disease. Blood, 2020. e-Pub 2020.
Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Faya L, Lee HJ, Iyer SP, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Flowers C, Tummala S, Ramdial J, Yalniz FF, Hawkins M, Rezvani K, Champlin RE, Shpall EJ, Neelapu SS, Kebriaei P, Ahmed S. The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL). Blood, 2020. e-Pub 2020.
Saini N, Junsheng, Timmons M, Alousi AM, Anderlini P, Andersson BS, Hosing C, Ramdial J, Kebriaei P, Popat UR, Qazilbash MH, Shpall EJ, Srour SA, Valdez BC, Dabaja BS, Pinnix CC, Gunther JR, Maadani F, Rondon G, Champlin RE, Nieto Y. High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) with Consolidative Radiation Therapy (RT) for Relapsed or Refractory (R/R) Primary Mediastinal B-Cell Lymphoma (PMBCL): 20-Year Experience at MD Anderson Cancer Center (MDACC). Blood, 2020. e-Pub 2020.
Saini N, Ma J, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing C, Nieto Y, Kebriaei P, Alousi AM, Mehta RS, Srour SA, Khouri IF, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. African-Americans Multiple-Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplant Have Similar Survival Outcomes Compared to Whites: A Propensity-Score Matched Analysis. Blood, 2020. e-Pub 2020.
Srour SA, Bashir Q, Milton DR, Nieto Y, Mehta RS, Saini N, Delgado R, Rondon G, Ciurea SO, Popat UR, Khouri IF, Kebriaei P, Manasanch EE, Hosing C, Patel KK, Lee HC, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Long-Term Survival for Myeloma after Autologous Stem Cell Transplantation. Blood, 2020. e-Pub 2020.
Oran B, Ciurea SO, Mehta RS, Alousi AM, Rondon G, Popat UR, Marin D, Daher M, Im JS, Kebriaei P, Alatrash G, Champlin RE. Transplant Outcomes with Fludarabine and Melphalan in High Risk AML Patients By Donor Types. Blood, 2020. e-Pub 2020.
Saberian C, Abdel-Wahab N, Abudayyeh A, Rafei H, Joseph J, Daher M, Gruschkus SK, Knape C, Whited L, Gulbis A, Marcotulli M, Rondon G, Popat UR, Mehta RS, Konopleva M, Oran B, Ohanian M, Ravandi F, Garcia-Manero G, Alousi AM, Daver N, Champlin RE, Diab A, Alatrash G. Lower Risk of Graft Versus Host Disease after Exposure to Checkpoint Inhibitors with the Use of Post-Transplant Cyclophosphamide Prophylaxis. Blood, 2020. e-Pub 2020.
Yalniz FF, Saliba RM, Yucel OK, Garcia-Manero G, Ramdial J, Popat U, Ciurea SO, Kebriaei P, Alousi AM, Alatrash G, Bashir Q, Hosing C, Marin D, Rohtes, Mehta, Olson AL, Rezvani K, Shpall EJ, Rondon G, Champlin RE, Oran B. Somatic Mutations Improve Risk Classification By Cytogenetic Abnormalities in Patients with Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation. Blood 134(Supplement 1), 2019. e-Pub 2019.
Champlin RE, Popat U, Oran B, Ciurea SO, Kebriaei P, Alousi AM, Alatrash G, Bashir Q, Khouri IF, Hosing C, Anderlini P, Jones RB, Marin D, Mehta R, Nieto Y, Olson AL, Qazilbash MH, Rezvani K, Shpall EJ, Chen J, Rondon G, McMullin B, Al Jahdhami VP, Kawedia J, Valdez BC, Junsheng, Thall PF, Andersson BS. A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS. Blood 134(Supplement 1), 2019. e-Pub 2019.
Wang Y, Young KH, Milton DR, Ledesma C, Jabbour E, Xu-Monette ZY, Molldrem JJ, Anderlini P, Alousi AM, Bashir Q, Daher M, Fayad LE, Iyer SP, Kebriaei P, Marin D, Mehta RS, Olson AL, Popat U, Samaniego F, Westin JR, Qazilbash MH, Im JS, Rondon G, Gulbis A, Champlin RE, Khouri IF. Clinical Relevance of MYC/BCL2 and Cell of Origin in Patients with Relapsed Diffuse Large B-Cell Lymphoma Treated with Autologous Stem Cell Transplantation. Blood 134(Supplement 1), 2019. e-Pub 2019.
Khouri IF, MD, Milton DR, Ledesma C, Nastoupil LJ, Jabbour E, Anderlini P, Bashir Q, Ciurea SO, Daher M, Fayad LE, Im JS, Iyer SP, Marin D, Mehta RS, Molldrem JJ, Olson AL, Oran B, Popat U, Qazilbash M, Srour S, Samaniego F, Rondon G, Medeiros L, Gulbis A, Champlin RE. Nonmyeloablative Allogeneic Transplantation (NMAT) Confers an Overall Survival Benefit with Similar Non-Relapse Mortality When Compared to Autologous Stem Transplantation (ASCT) for Patients (pts) with Relapsed Follicular Lymphoma (FL). Blood 134(Supplement 1), 2019. e-Pub 2019.
Ciurea SO, Bassett R, Soebbing D, Rondon G, Cao K, Olson AL, Bashir Q, Shpall EJ, Devine S, Pasquini MC, Martin AS, Lee DA, Champlin RE. Improved Outcomes for Patients Receiving High-Doses of IL-21 Ex Vivo Expanded NK Cells after Haploidentical Transplantation (haploSCT): Long-Term Follow-up of a Phase 1/2 Clinical Trial with Comparison to CIBMTR Controls. Blood 134(Supplement 1), 2019. e-Pub 2019.
Popat U, Saliba RM, Mehta RS, Olson AL, Chen J, Ganesh C, Rondon G, Woodworth G, McMullin B, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing C, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Saini N, Srour S, Rezvani K, Qazilbash MH, Molldrem JJ, Shpall EJ, Andersson BS, Champlin RE. Reduced Severe aGVHD and Improved Survival Using Post Transplant Cyclophosphamide/Tacrolimus/Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receiving Myeloablative Fractionated Busulfan Conditioning Regimen. Blood 134(Supplement 1), 2019. e-Pub 2019.
Koller P, Saliba RM, Ledesma C, Rondon G, Popat U, Alousi AM, Mehta RS, Oran B, Olson AL, Hosing C, Qazilbash MH, Khouri IF, Ciurea SO, Shpall EJ, Jorgensen JL, Wang SA, Jain N, Jabbour E, Kantarjian HM, Champlin RE, Konopleva MY, Kebriaei P. Allogeneic Hematopoietic Cell Transplantation May Improve Long-Term Outcomes in Patients with Ph-like Acute Lymphoblastic Leukemia with CRLF2 Overexpression. Blood 134(Supplement 1), 2019. e-Pub 2019.
Ciurea SO, Varma A, Kongtim P, Srour S, Bashir Q, Alousi AM, Mehta RS, Oran B, Popat U, Hosing C, Rondon G, Chen J, Olson AL, Konopleva MY, Champlin RE. Optimal Conditioning for Older Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Propensity Score Analysis. Blood 134(Supplement 1), 2019. e-Pub 2019.
Patel B, Sheshadri A, Saliba RM, Rondon G, Ahmed T, Arain MH, Mehta RS, Popat UR, Hosing CM, Bashoura L, Dickey BF, Champlin RE, Alousi AM. Azithromycin Exposure Following Hematopoietic Stem Cell Transplantation Is Associated with an Increased Risk of Cancer Relapse in Acute Leukemia. Biology of Blood and Marrow Transplatation 25(3):Supplement S231-S232, 2019. e-Pub 2019.
Saliba RM, Rondon G, Chen J, Ledesma C, Champlin RE, Ciurea SO. Endothelial Activation and Stress Index (EASIX) Is Associated with Fluid Overload and Survival in Recipients of Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 25(3 Supplement):S32-S33, 2019. e-Pub 2019.
Mukherjee A, Milton D, Ledesma C, Olson A, Alatrash G, Anderlini P, Alousi AM, Bashir Q, Ciurea SO, Kebriaei P, Marin D, Molldrem JJ, Oran B, Popat UR, Qazilbash MH, Rondon G, Champlin RE, Gulbis AM, Khouri IF. Influence of the Intensity of the Allogeneic Conditioning Regimen on the Risk of Hemorrhagic Cystitis (HC) in Patients Receiving Post- Transplant Cyclophosphamide (PT-Cy) As Gvhd Prophylaxis. Biology of Blood and Marrow Transplantation 25(3):Supplement S147-S148, 2019. e-Pub 2019.
Saini N, Saliba RM, Patel RD, Abdulrazzaq MN, Hosing CM, Alousi AM, Anderlini P, Popat UR, Qazilbash MH, Shpall EJ, Kebriaei P, Nastoupil LJ, Westin JR, Rondon G, Andersson BS, Champlin RE, Muzzafar TR, Nieto Y, Ahmed S. Does Cell of Origin Classification Impact Outcomes in Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplant. Biology of Blood and Marrow Transplantation 25(3):Supplemenmt S394-S395, 2019. e-Pub 2019.
Popat UR, Saliba RM, Olson A, Mehta RS, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Molldrem JJ, Nieto Y, Oran B, Qazilbash MH, Rezvani K, Rondon G, Shpall EJ, Varma A, Andersson BS, Champlin RE. Comparison of Tacrolimus and Post-Transplant Cyclophosphamide (PTCy) with Tacrolimus and Methotrexate (Tac/MTX) Gvhd Prophylaxis in Patients with AML Undergoing Transplantation from Matched Related or Unrelated Donors. Biology of Blood and Marrow Transplantation 25(3):Supplement S235-S236, 2019. e-Pub 2019.
Varma A, Abraham SC, Saini N, Bashir Q, Rondon G, Srour SA, Mehta RS, Olson A, Oran B, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Marin D, Khouri IF, Ciurea SO, Qazilbash MH, Rezvani K, Shpall EJJ, Champlin RE, Popat UR. Idiopathic Portal Hypertension Related Refractory Ascites (IPHRA) after Allogeneic Stem Cell Transplant. Biology of Blood and Marrow Transplantation 25(3):Supplement S144-S145, 2019. e-Pub 2019.
Srour SA, Milton D, Bashir Q, Mehta RS, Delgado R, Rondon G, Nieto Y, Hosing CM, Popat UR, Ciurea SO, Patel K, Lee HC, Manasanch E, Thomas S, Weber D, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan Dose Intensity for Autologous Stem Cell. Biology of Blood and Marrow Transplantation 25(3 Supplement):S21, 2019. e-Pub 2019.
Khouri IF, Milton DR, Ledesma C, Erwin WD, Jabbour EJ, Alatrash G, Anderlini P, Bashir Q, Ciurea SO, Im JS, Marin D, Mehta RS, Molldrem JJ, Olson AL, Oran B, Popat U, Qazilbash MH, Rondon G, Champlin RE, Medeiros L, Gulbis A. Durability Results of Non-Myeloablative (NMA) Allogeneic Stem Cell Transplantation (alloSCT) for Relapsed Follicular Lymphoma: 17- Year Experience. Blood 132(Supplement 1), 2018. e-Pub 2018.
Kongtim P, Parmar S, Milton DR, Ramos Perez JM, Rondon G, Chen J, Chilkulwar AR, Alatrash G, Alousi AM, Andersson BS, Im JS, Hosing C, Bashir Q, Khouri IF, Kebriaei P, Oran B, Popat U, Champlin RE, Ciurea SO. Hematopoietic Cell Transplant-Composite Risk (HCT-CR) — a Novel Prognostic Model to Predict Transplant Outcomes. Blood 132(Supplement 1), 2018. e-Pub 2018.
Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Oran B, Hosing C, Bashir Q, Olson AL, Nieto Y, Alousi AM, Kebriaei P, Srour SA, Mehta RS, Anderlini P, Shpall EJ, Qazilbash MH, Khouri IF, Fayad LE, Lee HJ, Fowler NH, Parmar S, Westin JR, Hagemeister F, Champlin RE, Ciurea SO. Allogeneic Transplantation for Lymphoid Malignancies with Fludarabine and Melphalan Conditioning and Different Donor Types. Blood 132(Supplement 1), 2018. e-Pub 2018.
Lin P, Veltri LW, Rezvani K, Oran B, Ahmed S, Alatrash G, Mehta RS, Rondon G, Kebriaei P, Popat U, Nieto Y, Hosing C, Jones RB, Qazilbash MH, Khouri IF, Shpall EJ, Champlin RE, Marin D. Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia. Blood 132(Supplement 1), 2018. e-Pub 2018.
Ciurea SO, Borges Bittencourt MC, Milton DR, Cao K, Kongtim P, Rondon G, Chen J, Konopleva MY, Ramos Perez JM, Elshazly M, Aljadayeh M, Alvarez M, Im JS, Alatrash G, Mehta RS, Popat U, Bashir Q, Oran B, Hosing C, Khouri IF, Kebriaei P, Champlin RE. Is a Matched Unrelated Donor Search Needed for All Allogeneic Transplant Candidates?. Blood 132(Supplement 1), 2018. e-Pub 2018.
Khouri IF, Milton DR, Ledesma C, Jabbour EJ, Alatrash G, Anderlini P, Alousi AM, Bashir Q, Ciurea SO, Hymes S, Marin D, Molldrem JJ, Olson AL, Oran B, Popat U, Qazilbash MH, Rondon G, Champlin RE, Gulbis A. Influence of the Intensity of the Conditioning Regimens on the Risks of Gvhd in Patients Receiving Rituximab Prophylaxis during Allogeneic Stem Cell Transplantation (alloSCT). Blood 132(Supplement), 2018. e-Pub 2018.
Saini NY, Varma A, Ma J, Milton DR, Patel R, Hasan O, Bashir Q, Nieto Y, Mukherjee A, Delgado R, Rondon G, Popat U, Hosing C, Kebriaei P, Alousi AM, Ahmed S, Mehta RS, Ciurea SO, Khouri IF, Shpall EJ, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. mpact of t(11;14) on the Outcome of Autologous Transplantation in Multiple Myeloma: A Matched-Pair Analysis. Blood 132(Supplement 1), 2018. e-Pub 2018.
Varma A, Saini NY, Sui D, Milton DR, Hasan O, Mukherjee A, Bashir Q, Rondon G, Srour SA, Popat U, Hosing C, Nieto Y, Kebriaei P, Alousi AM, Mehta RS, Khouri IF, Weber DM, Thomas SK, Manasanch EE, Lee HC, Patel KK, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation. Blood 132(Supplement 1), 2018. e-Pub 2018.
Daher M, Cao K, Basar R, Marin D, Sekine T, Rondon G, Zhao W, Smith NT, Wang Q, Li L, Saliba RM, Kiran Pingali SR, Popat U, Hosing C, Olson AL, Oran B, Mehta RS, Champlin RE, Shpall EJ, Rezvani K. Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation after Double Cord Blood Transplantation. Blood 132(Supplement 1), 2018. e-Pub 2018.
Saini NY, Patel R, Varma A, Bashir Q, Hasan O, Delgado R, Rondon G, Mukherjee A, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Long-Term Durable Responses after Autologous Stem Cell Transplantation in POEMS Syndrome. Blood 132(Supplement 1), 2018. e-Pub 2018.
Kongtim P, Parmar S, Milton D, Rondon G, Chen J, Oran B, Popat UR, Hosing CM, Bashir Q, Kebriaei P, Khouri IF, Champlin RE, Ciurea SO. Validation of a Predictive Model for Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome Receiving Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 24(3):Supplement S107, 2018. e-Pub 2018.
Qazilbash MH, Milton D, Bashir Q, Shah N, Nieto Y, Popat UR, Mehta RS, Kebriaei P, Delgado R, Rondon G, Weber D, Thomas S, Lee HC, Manasanch E, Patel K, Orlowski RZ, Champlin RE. Continuing Improvement in the Outcome of Patients with Multiple Myeloma Undergoing Auto-HCT Over Three Decades. Biology of Blood and Marrow Transplantation 24(3):Supplement S50-S51, 2018. e-Pub 2018.
Kebriaei P, Huls H, Olivares S, Orozco AF, Su S, Maiti SN, Groot ED, Smith A, Yang Y, Rondon G, Qazilbash MH, Ciurea SO, Alousi AM, Nieto Y, Marin DC, Popat U, Hosing C, Kantarjian HM, Rezvani K, Shpall EJ, Champlin RE, N Cooper LJ, Singh H. Long Term Follow up after Adoptive Transfer of CD19-Specific CAR+ T Cells Genetically Modified Via Non-Viral Sleeping Beauty S ystem Following Hematopoietic Stem Cell Transplantation (HSCT). Blood 130(Suppl 1):2059, 2017. e-Pub 2017.
Kongtim P, Parmar S, Milton DR, Rondon G, Chen J, Oran B, Popat U, Hosing C, Bashir Q, Kebriaei P, Khouri IF, Champlin RE, Ciurea SO. Validation of a Predictive Model for Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome Receiving Hematopoietic Stem Cell Transplantation. Blood 130(Suppl 1):4511, 2017. e-Pub 2017.
Gowda L, Saliba RM, Shah MV, Rondon G, Badar I, Olson AL, Ciurea SO, Kebriaei P, Srour SA, Parmar S, Nieto Y, Ahmed S, Mehta RS, Alatrash G, Marin DC, Andersson BS, Oran B, Bashir Q, Qazilbash MH, Hosing C, Khouri IF, Alousi AM, Anderlini P, Shpall EJ, Rezvani K, Champlin RE, Popat U. Graft Failure Post Allogeneic Stem Cell Transplant: Conditioning Regimen Improves Engraftment and Survival. Blood 130(Suppl 1):3267, 2017. e-Pub 2017.
Gowda L, Alijadayeh M, Marin DC, Ledesma C, Rondon G, Popat U, Alousi AM, Oran B, Shah MV, Ahmed S, Kanagal-Shamanna R, Ciurea SO, Shpall EJ, Luthra R, Hosing C, Qazilbash MH, Rezvani K, Jabbour EJ, Patel KP, Ravandi F, Kantarjian HM, Champlin RE, Kebriaei P. Early Maintenance with Tyrosine Kinase Inhibitors Post Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Improves Survival in Ph+ Acute Lymphoblastic Leukemia (ALL) Patients. Blood 130(Suppl 1):1992, 2017. e-Pub 2017.
Besien KV, Artz A, Champlin RE, Guarneri D, Bishop MR, Chen J, Shore TB, Liu H, Rondon G, Mayer SA, Ciurea SO. Fludarabine Melphalan Conditioning Followed By T-Replete Haplo Identical (Haplo) Transplantation or Haplo Cord (HC) Transplantation. Blood 130(Suppl 1):3328, 2017. e-Pub 2017.
Ciurea SO, Soebbing D, Rondon G, Cao K, Alatrash G, Ahmed S, Popat U, Oran B, Bashir Q, Kebriaei P, Kaur I, Rezvani K, Shpall EJ, Lee DA, Champlin RE. Interim Results of a Phase 2 Clinical Trial Using Mb-IL21 Ex Vivo Expanded NK Cells to Enhance Graft Versus Leukemia Effect for Patients with Myeloid Malignancies after Haploidentical Transplantation. Blood 130(Suppl 1):3179, 2017. e-Pub 2017.
Oran B, Saliba RM, Jorgensen JL, Shah MV, Marin DC, Wang SA, Ahmed S, Alousi AM, Andersson BS, Bashir Q, Ciurea SO, Rezvani K, Popat U, Rondon G, Kebriaei P, Shpall EJ, Champlin RE. The Prognostic Impact of Minimal Residual Disease on Risk of Progression and Progression Free Survival in Acute Myeloid Leukemia. Blood 130(Suppl 1):2031, 2017. e-Pub 2017.
Ciurea SO, Saliba RM, Chen J, Rondon G, Popat U, Parmar S, Anderson B, Alousi AM, Ahmed S, Bashir Q, Alatrash G, Hosing C, Olson AL, Mehta RS, Rezvani K, Shpall EJ, Khouri IF, Kebriaei P, E Champlin AR. Allogeneic Transplantation for TP53+ AML: Prognostic Factors for Survival. Blood 130(Suppl 1):1938, 2017. e-Pub 2017.
Abudayyeh A, Lin HY, Abdelrahim M, Rondon G, Andersson B, Martinez C, Tarrand J, Chemaly R, Kontoyiannis DP, Marin D, Olson AL, Champlin RE, Shpall EJ, Rezvani K. 3.A validated symptomatic BKV risk assessment score in patient post allogeneic stem cell transplant. Journal of Clinical Oncology, 2017. e-Pub 2017.
Hwang J, Suarez-Almazor ME, Cantor SB, Barbo AG, Lin HY, Ahmed S, Gregor MC, Donato-Santana C, Eng C, Ferrajoli A, Fisch M, McLaughlin P, Simon GR, Rondon G, Shpall EJ, F Lok AS. 2.Impact of the timing of hepatitis B virus (HBV) identification and anti-HBV therapy initiation on the risk of adverse liver outcomes in patients receiving cancer therapy. Journal of Clinical Oncology, 2017. e-Pub 2017.
Lu H, Murphy WA, Ebede CC, Karim E, Rondon G, Leung CH, Liu S, Champlin RE, Pundole X. Exploration of risk factors for osteoporotic fracture following hematopoietic stem cell transplantation. Journal of Clinical Oncology, 2017. e-Pub 2017.
Shah MV, Saliba RM, Jorgensen JL, Wang SA, Alousi AM, Andersson BS, Bashir Q, CiureaPartow Kebriaei SO, Marin D, Patel KP, Popat UR, Rezvani K, Rondon G, Shpall EJ, Champlin RE, Oran B. Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia Patients. Biology of Blood and Marrow Transplantation 23(3):S40-S41, 2017. e-Pub 2017.
Ramlal R, Rondon G, Lahoti A, Champlin RE, Alousi AM. Improved Renal Outcomes in Patients Converted From Tacrolimus to Sirolimus after Developing Acute Kidney Injury Post Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 23(3):S293-S294, 2017. e-Pub 2017.
Ciurea SO, Labopin M, Polge E, Kongtim P, Rondon G, Socié G, Volin L, Passweg J, Chevallier P, Beelen DW, Milpied N, Blaise D, Comelissen J, Fegueux N, Mohty M, Savani BN, Champlin RE, Nagler A. Outcomes of Allogeneic Hematopoietic Cell Transplantation for AML with Complex Karyotypes: A Retrospective Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and MD Anderson Cancer Center. Biology of Blood and Marrow Transplantation 23(3):S38, 2017. e-Pub 2017.
Hill L, Saliba RM, Chen J, Rondon G, Qazilbash MH, Popat UR, Shah N, Neumann JL, Hymes SR, Hosing CM, Kebriaei P, Oran B, Nieto Y, Olson A, Ciurea SO, Marin D, Champlin RE, Shpall EJ, Alousi AM. Predictors for Steroid Tapering in Patients with Acute Graft-Versus-Host Disease and Their Impact on Graft-Versus-Host Disease Response and Non-Relapse Mortality: Older Age and Co-Morbidities Are Associated with Quicker Tapering and Worse Outcomes. Biology of Blood and Marrow Transplantation 23(3):S371, 2017. e-Pub 2017.
Ciurea SO, Labopin M, Polge E, Kongtim P, Rondon G, Socie G, Volin L, Passweg JR, Chevallier P, Beelen DW, Vigouroux S, Blaise D, Cornelissen JJ, Fegueux N, Mohty M, Savani BN, Champlin RE, Nagler A. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia (AML) with Complex Karyotypes (CK): A Retrospective Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) and MD Anderson Cancer Center (MDACC). Blood, 2016. e-Pub 2016.
Hill L, Saliba RM, Chen J, Rondon G, Qazilbash MH, Popat UR, Shah N, Neumann JL, Hymes SR, Hosing C, Kebriaei P, Nieto Y, Oran B, Olson A, Ciurea SO, Rezvani K, Marin D, Champlin RE, Shpall EJ, Alousi AM. Predictors for Steroid Tapering in Patients with Acute Graft-Versus-Host Disease and Their Impact on Graft-Versus-Host Disease Response and Non-Relapse Mortality: Older Age and Co-Morbidities Are Associated with Quicker Tapering and Worse Outcomes. Blood, 2016. e-Pub 2016.
Cerrada SL, Marin D, Rondon G, Ledesma C, Popat UR, Olson A, Alousi A, Oran B, Ahmed S, Ciurea SO, Patel K, Shpall EJ, Hosing C, Qazilbash MH, Shah N, Rezvani K, Jabbour E, Kantarjian HM, Champlin RE, Kebriaei P. Additional Consolidation after Attaining Second Complete Remission Results in Superior Outcomes after Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Lymphoblastic Leukemia. Blood, 2016. e-Pub 2016.
Cerrada SL, Marin D, Rondon G, Ledesma C, Popat UR, Olson AL, Alousi AM, Oran B, Ahmed S, Ciurea SO, Patel K, Shpall EJ, Hosing C, Qazilbash MH, Shah N, Rezvani K, Jabbour E, Kantarjian HM, Champlin RE, Kebriaei P. Impact of New Anti-Leukemia Agents on Transplant Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL) Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) in Second Complete Remission. Blood, 2016. e-Pub 2016.
Mohyuddin GR, Faisal MS, Shah N, Bashir Q, Hosing C, Patel K, Popat UR, Parmar S, Rondon G, Delgado R, Weber DM, Shah JJ, Thomas S, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH. A Case Control Study of Syngeneic Transplantation Versus Autologous Transplantation for Multiple Myeloma: Two Decades of Experience at MD Anderson. Blood, 2016. e-Pub 2016.
Maher OM, Saliba RM, Alousi AM, Champlin RE, Shpall EJ, Tewari P, Hymes SR, Neumann JL, Overman BJ, Chen J, Rondon G, Song HW, Hofferek CJ, Tran DQ. High TCR Vbeta Skewing in CD4+ and Low in CD8+ Is Associated with Development of Chronic Graft-Versus-Host Disease. Blood, 2016. e-Pub 2016.
Srour SA, Saliba RM, Delgado R, Qazilbash MH, Bashir Q, Shah N, Popat UR, Ahmed S, Patel K, Jones R, Rondon G, Champlin RE, Nieto Y. Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Blood, 2016. e-Pub 2016.
Ciurea SO, Lee DA, Denman C, Schafer J, Bassett Jr RL, Cao K, MS, Rondon G, Chen J, Soebbing D, Willis DB, Ahmed S, Bashir Q, Kebriaei P, Khouri IF, Oran B, Parmar S, Popat UR, Hosing C, Yvon E, Rezvani K, Shpall EJ, Champlin RE. Safety and Feasibility of Administration of High Doses of Ex Vivo Expanded NK Cells for Prevention of Disease Relapse after Transplantation for Patients with Myeloid Malignancies - Final Results of a Phase I Clinical Trial. Blood, 2016. e-Pub 2016.
Yucel OK, Saliba RM, Rondon G, Ahmed S, Alousi AM, Andersson BS, Bashir Q, Ciurea SO, Khouri IF, Nieto Y, Popat UR, Marin D, Rezvani K, Kebriaei P, Shah N, Olson AL, Shpall EJ, Champlin RE, Oran B. Comparable Outcomes of Therapy-Related and De Novo Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2016. e-Pub 2016.
Kongtim P, A Adekola KU, Milton DR, Ramlal R, Jimenez AM, Chen J, Rondon G, Ahmed S, Oran B, Popat UR, Cortes J, Champlin RE, Ciurea SO. Haploidentical Donors in Addition to Transplantation in Chronic Phase Associate with Improved Gvhd-Free Relapse-Free Survival (GRFS) for Patients with Advanced CML. Blood, 2016. e-Pub 2016.
Kebriaei P, Basset Jr RL, Ledesma C, Rondon G, Oran B, Ciurea SO, Alousi AM, Popat UR, Patel KK, Ahmed S, Olson AL, Bashir Q, Shah N, Jones R, Rezvani K, Nieto Y, Khouri IF, Qazilbash MH, Hosing CM, Shpall EJ, Champlin RE, Andersson BS. Clofarabine (Clo) Plus Busulfan (Bu) Is an Effective Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Lymphoblastic Leukemia (ALL): Long-Term Study Results. Blood, 2015. e-Pub 2015.
Ragon BK, Gulbis AM, Saliba RM, Chen J, Rondon G, Popat UR, Nieto Y, Oran B, Olson AL, Patel K, Hosing CM, Qazilbash MH, Shah N, Kebriaei P, Shpall EJ, Champlin RE, Alousi AM. Pentostatin Therapy for Steroid-Refractory Acute Graft Versus Host Disease: Identifying Those Who May Benefit. Blood, 2015. e-Pub 2015.
Kebriaei P, Ciurea SO, Huls MH, Singh H, Olivares S, Su S, Figliola MJ, Kumar P, Jena B, Forget M, Ang S, Jackson R, Liu T, McNiece IK, Rondon G, Hackett P, Kantarjian HM, Lee DA, Popat UR, Alousi A, Oran B, Shah N, Hosing CM, Marin D, Rezvani K, Shpall EJ, Champlin RE. Pre-Emptive Donor Lymphocyte Infusion with CD19-Directed, CAR-Modified T Cells Infused after Allogeneic Hematopoietic Cell Transplantation for Patients with Advanced CD19+ Malignancies. Blood, 2015. e-Pub 2015.
Kongtim P, Popat UR, Jimenez AM, Gabella S, El Fakih RO, Rondon G, Chen J, Bueso-Ramos CE, Borthakur G, Pemmaraju N, Garcia-Manero G, Kantarjian HM, Alousi AM, Hosing CM, Anderlini P, Khouri IF, Kebriaei P, Andersson BS, Oran B, Rezvani K, Marin D, Shpall EJ, Champlin RE, Ciurea SO. Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Survival for Patients with Chronic Myelomonocytic Leukemia. Blood, 2015. e-Pub 2015.
Im JS, Saliba RM, Abraham SC, Ross W, Rondon G, Rashid A, Shpall EJ, Popat UR, Qazilbash M, Hosing CM, Oran B, Shah N, Champlin RE, Alousi AM. Histologic Confirmation for Patients Presenting with Gastrointestinal Graft Versus Host Disease: How to Interpret Histologic Grade 1 (Does It Matter)?. Blood, 2015. e-Pub 2015.
Gaballa S, Ge I, El Fakih RO, Brammer JE, Wang SA, Lee DA, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom AE, Al-Atrash G, Korbling M, Oran B, Kebriaei P, Ahmed S, Shah N, Rezvani K, Marin D, Bashir Q, Alousi AM, Nieto Y, Qazilbash MH, Hosing CM, Popat UR, Shpall EJ, Khouri IF, Champlin RE, Ciurea SO. Results of a Two-Arm Phase II Clinical Trial Using Post-Transplantation Cyclophosphamide for Prevention of Graft-Versus-Host Disease in Haploidentical and Mismatched Unrelated Donors Hematopoietic Stem-Cell Transplantation. Blood, 2015. e-Pub 2015.
Ramlal R, Gaballa S, Chen J, Rondon G, Oran B, Ahmed S, Bashir Q, Rezvani K, Marin D, Alousi AM, Kebriaei P, Qazilbash M, Hosing C, Popat UR, Shpall EJ, Champlin R, Ciurea SO. Outcomes of Haploidenitical Stem Cell Transplants for De Novo Acute Myeloid Leukemia, Myelodysplastic Syndrome and Acute Myeloid Leukemia Arising from MDS: The MD Anderson Experience. Blood, 2015. e-Pub 2015.
Mehta RS, Saliba RM, Chen J, Rondon G, Hammerstrom AE, Alousi AM, MD, Qazilbash MH, MD, Bashir Q, Ahmed S, Popat UR, Hosing CM, Khouri IF, Shpall EJ, Champlin RE, Ciurea SO. Post-Transplantation High Dose Cyclophosphamide As Gvhd Prophylaxis in 9/10 HLA-Matched Unrelated Donors Hematopoietic Stem Cell Transplantation. Blood, 2015. e-Pub 2015.
Rondon G, Saliba RM, Chen J, Ledesma C, Alousi AM, Oran B, Hosing CM, Kebriaei P, Khouri IF, Shpall EJ, Popat UR, Champlin RE, Ciurea SO. Fluid Overload As New Toxicity Category Has a Strong Impact on Non Relapse Mortality and Survival in Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2015. e-Pub 2015.
Brammer JE, Saliba RM, Jorgensen JL, Ledesma C, Rondon G, Poon M, Koh LP, Dibb W, Fan G, Saliba CK, Wang S, Popat UR, Shpall EJ, Ravandi F, Kantarjian H, Maziarz RT, Champlin RE, Hosing CM, Kebriaei P. Multi-Center Analysis of the Effect of Disease Subtype and Minimal Residual Disease on Allogeneic Stem Cell Transplantation Outcomes in T-Cell Acute Lymphoblastic Leukemia (T-ALL). Blood, 2015. e-Pub 2015.
Ciurea SO, Lee DA, Cao K, Rondon <, Chen J, Willis DB, Ahmed S, Yvon E, Rezvani K, Shpall EJ, Champlin RE. Phase I Trial of IL-21 Ex Vivo Expanded NK Cells Administration to Prevent Disease Relapse after Haploidentical Stem-Cell Transplantation for Myeloid Leukemias. Blood, 2015. e-Pub 2015.
Im JS, Saliba RM, Abraham SC, Rashid A, Ross W, Nieto Y, Shpall EJ, Oran B, Olson A, Ahmed S, Popat UR, Rondon G, Qazilbash MH, Shah N, Champlin RE, Alousi AM. Gastrointestinal Acuity Score (GAS): A Comprehensive Risk Score Incorporating Histologic Grade and Clinical Factors to Predict Need for Second Line Therapy, Non-Relapse Mortality, and Overall Survival in Lower Gastrointestinal Graft Vs. Host Disease. Blood, 2015. e-Pub 2015.
Huls H, Singh H, Olivares S, Figliola M, Maiti S, Shihuang S, Kumar PR, Jena B, Forget MA, Ang S, Rineka J, Liu T, McNiece IK, Rondon G, Hackett P, Wierda WG, O'Brien S, Keating MJ, Kantarjian HM, Hosing CM, Shpall EJ, Champlin, Cooper LJ. Adoptive Therapy Using Sleeping Beauty Gene Transfer System and Artificial Antigen Presenting Cells to Manufacture T Cells Expressing CD19-Specific Chimeric Antigen Receptor. Blood, 2014. e-Pub 2014.
Ciurea SO, Kongtim P, Rondon G, Chen J, Champlin RE. Should a Personalized Approach be Also Applied to Hematopoietic Stem-Cell Transplantation (HSCT)? Transplantation for Older Patients with Hematologic Malignancies Suggests so. Blood, 2014. e-Pub 2014.
Ahmed S, Shpall EJ, Gulbis A, Jones R, Martinez CS, Rondon G, Rezvani K, Oran B, Olson A, Shah N, Parmar S, Popat UR, Alousi AM, Nieto Y, Hosing CM, Bashir Q, Kebriaei P, Qazilbash MH, Champlin RE, Mulanovich VE. Assessment of Incidence Toxoplasma Gondii Infection and Outcomes in Allogeneic Stem Cell Patients. Blood, 2014. e-Pub 2014.
Oran B, Cao K, Saliba RM, Hosing CM, Popat UR, Lima MD, Carmazzi Y, Alousi A, Kebriaei P, Nieto Y, Rondon G, Willis D, Shah N, Parmar S, Olson A, Moore B, Champlin RE, Rezvani K, Shpall EJ. Higher Allele Level HLA Matching Improves Prognostication after Double Umbilical Cord Blood (dUCB) Transplantation for Hematological Malignancies. Blood, 2014. e-Pub 2014.
Khouri IF, Saliba RM, Xu-Monette ZY, Korbling M, Rondon G, Valverde R, Alousi AM, Anderlini P, Ahmed S, Ciurea SO, Fayad L, Oran B, Parmar S, Popat UR, Westi JR, Turturro F, Medeiros L, Gulbis AM, Young KH. Outcomes Following Allogeneic Stem Cell Transplantation (AlloSCT) in Patients with Primary Mediastinal (PMBL), Germinal Center B (GCB) and Non-GCB Cell-like Diffuse Large B Cell Lymphomas (DLBCL). Blood, 2014. e-Pub 2014.
Oran B, Rima SM, Andersson BS, de Lima MJ, Popat UR, Khouri IF, Kebriaei P, Bashir Q, Ahmed S, Shpall EJ, Champlin RE, Rondon G. Improved Progression-Free Survival with Minimal Toxicity after Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients with Hematological Malignancy. Blood, 2014. e-Pub 2014.
Tamari R, Oran B, Hilden P, Papadopoulos EB, Kongtim P, Rondon G, Jakubowski AA, Andersson BS, Devlin SM, Ahmed S, Young JW, Popat UR, Chen J, Lima MD, Sergio Giralt RJO, Champlin RE, Castro-Malaspina H. Allo- HSCT for Advanced Myelodysplastic Syndrome:MSKCC Vs MDACC. Blood, 2014. e-Pub 2014.
Bock FM, Lu G, Shah N, Bashir Q, Patel KK, Popat UR, Hosing CM, Gaballa S, Korbling M, Delgado R, Rondon G, Orlowski RZ, Shah JJ, Manasanch EE, MD, Champlin RE, Qazilbash MH. Clinical Characteristics and Outcomes in Patients with Multiple Myeloma and CKS1B Gene Gain/Amplification after Autologous Stem Cell Transplantation. Blood, 2014. e-Pub 2014.
Gaballa S, Kongtim P, Rondon G, Chen J, Popat U, Ahmed S, Hosin CM, Oran B, Kebriaei P, Parmar S, Shah N, Khouri IF, Champlin RE, Ciurea SO. Feasibility and Outcomes of Haploidentical Transplantation for Elderly Patients with Advanced Hematological Malignancies: The MD Anderson Cancer Center Experience. Blood, 2014. e-Pub 2014.
Hamdi A, Mawad R, Stasi AD, Bassett R, Ferro R, Ram R, Rondon G, Champlin RE, Sandmaier BM, Doney KC, Bar M, Kebriaei P. Central Nervous System Relapse In Adults With Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2013. e-Pub 2013.
Gettys SC, Gulbis AM, Wilhelm K, Dinh YT, Rondon G, Qazilbash MH. Modified-CVAD Or Modified-Cbad Compared To High Dose Cyclophosphamide For Peripheral Blood Stem Cell Mobilization In Patients With Multiple Myeloma. Blood, 2013. e-Pub 2013.
Popat UR, Oran B, Hosing CM, Kebriaei P, Rezvani K, Parmar S, Shah N, Bollard CM, Molldrem JJ, Nieto Y, Andersson BS, Alousi A, Jones RB, MD, N Cooper LJ, MD, Qazilbash MH, Bashir Q, Ahmed S, Bosque D, Chen J, McCarty J, Rondon G, Munsell M, McNiece IK, Kaur I, Yvon E, Annandale K, Olchesky S, de Lima MJ, Champlin RE, Miller L, Paradiso L, Koh L, Zweidler-McKay PA, Shpall EJ. Ex Vivo Fucosylation Of Cord Blood Accelerates Neutrophil and Platelet Engraftment. Blood, 2013. e-Pub 2013.
Oran B, Kongtim P, Lima MD, Popat UR, Garcia-Manero G, Jabbour EJ, Abruzzo LV, Chen J, Rondon G, Andersson BS, Alousi A, Ciurea SO, Shpall EJ, Champlin RE. Prior Hypomethylating Agents Or Chemotherapy Does Not Improve The Outcome Of Allogeneic Hematopoietic Transplantation For High Risk MDS. Blood, 2013. e-Pub 2013.
Khouri IF, Saliba RM, Xu-Monette ZY, Rondon G, Valverde R, Korbling M, Gulbis AM, Anderlini P, Sairah A, Hosing CM, Popat UR, Kebriaei P, Fayad LE, Westin JR, Turturro F, Medeiros L, Champlin RE, Young KH. Outcomes Following Autologous Stem Cell Transplantation (ASCT) In Patients With Germinal Center B (GCB) and Non-GCB Cell-Like Diffuse Large B Cell Lymphomas (DLBCL) According To Conditioning With BEAM-Rituximab (Standard vs. High-Dose) Vs. BEAM/Yttrium-90 Ibritumomab Tiuxetan (90YIT). Blood, 2013. e-Pub 2013.
Popat UR, Oran B, Hosing CM, Kebriaei P, Rezvani K, Parmar S, Shah N, Bollard CM, Molldrem JJ, Nieto Y, Andersson BS, Alousi A, Jones RB, N Cooper LJ, Qazilbash MH, Bashir Q, Ahmed S, Bosque D, Chen J, McCarty J, Rondon G, Munsell M, McNiece IK, Kaur I, Yvon E, Annandale K, Olchesky S, de Lima MJ, Champlin RE, Miller L, Paradiso L, Koh L, Zweidler-McKay PA, Shpall EJ. Ex Vivo Fucosylation Of Cord Blood Accelerates Neutrophil and Platelet Engraftment. Blood, 2013. e-Pub 2013.
Hobbs GS, Hilden P, Hamdi A, Goldberg JD, Poon M, Ledesma C, Devlin S, Rondon G, Papadopoulos EB, Jakubowski AA, O'Reilly RJ, Champlin RE, Giralt SA, Kebriaei P, Perales MA. Outcomes In Patients With Acute Lymphoblastic Leukemia In First Or Second Complete Remission Receiving Ex-Vivo T-Cell Depleted Or Unmodified Allografts: Comparison Of Results At Two Institutions. Blood, 2013. e-Pub 2013.
Kebriaei P, Huls H, Singh H, Olivares S, Figliola M, Kumar PR, Jena B, Andree M, Ang S, Jackson RN, Liu T, Bosque D, McNiece IK, Rondon G, Hackett P, Hosing CM, Shpall EJ, Champlin RE, N Cooper LJ. First Clinical Trials Employing Sleeping Beauty Gene Transfer System and Artificial Antigen Presenting Cells To Generate and Infuse T Cells Expressing CD19-Specific Chimeric Antigen Receptor. Blood, 2013. e-Pub 2013.
Parmar S, de Lima MJ, Lee DA, Worth L, Kongtim P, Petropoulos D, McNiece IK, Shpall EJ, Rondon G, Champlin RE. Is There An Expiration Date For Cord Blood Units In Storage. Blood, 2013. e-Pub 2013.
Stasi AD, Poon LM, Ferro R, Milton D, Rondon G, Wang SA, Hamdi A, Qazilbash MH, Ahmed S, Khouri I, Oran B, Hosing CM, Kebriaei P, Alousi A, Popat UR, Shpall EJ, Lee DA, Rezvani K, Champlin RE, Ciurea SO. Transplant Outcomes For Patients With AML/MDS Using Melphalan-Based Conditioning. Blood, 2013. e-Pub 2013.
Hamdi A, Mawad R, Stasi AD, Bassett R, Ferro R, Ram R, Rondon G, Champlin RE, Sandmaier BM, Doney KC, Bar M, Kebriaei P. Central Nervous System Relapse In Adults With Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2013. e-Pub 2013.
Kongtim P, Popat UR, Lima MD, Garcia-Manero G, Jabbour EJ, Chen J, Rondon G, Abruzzo LV, Ciurea SO, Shpall EJ, Champlin RE, Oran B. MD Anderson Scoring System (MDACC) Predicts Outcomes After Hematopoietic Stem Cell Transplantation (HSCT) Better Than Other Prognostic Classifications In MDS. Blood, 2013. e-Pub 2013.
Oran B, Poon M, Chen J, Rondon G, Ahmed S, Andersson BS, Bashir Q, Ciurea SO, Hosing CM, Parmar S, Qazilbash MH, Popat UR, Nieto Y, Alousi A, Jones RB, Rezvani K, Lima MD, Shpall EJ, Champlin RE, Kebriaei P. Comparable Outcomes After Sibling and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantations (HCT) In Adult Acute Lymphoblatic Leukemia (ALL) With First Complete Remission (CR). Blood, 2013. e-Pub 2013.
Kebriaei P, Huls H, Singh H, Olivares S, Figliola M, Kumar PR, Jena B, Jackson RN, Liu T, McNiece IK, Rondon G, Hackett P, Champlin RE, Shpall EJ, N Cooper LJ. Adoptive Immunotherapy Following Umbilical Cord Blood Transplantation Using The Sleeping Beauty System and Artificial Antigen Presenting Cells To Generate Donor-Derived T Cells Expressing a CD19-Specific Chimeric Antigen Receptor. Blood, 2013. e-Pub 2013.
Ciurea SO, Saliba RM, Bayraktar UD, Xie S, Rondon G, Parmar S, Kebriaei P, Montes N, Sharma M, Konopleva M, Nieto Y, Qazilbash MH, Alousi AM, Andersson BS, Hosing CM, Shpall EJ, Khouri IF, Lima MD, Champlin R. Improved Early Outcomes with T-Cell Replete (TCR) Compared with T-Cell Depleted (TCD) Haploidentical Stem Cell Transplantation (HaploSCT). Blood 118(21):149-150, 2011. e-Pub 2011.
Ahmed S, Chiattone A, Jones R, Sphall EJ, Farhan S, Rondon G, Nieto Y, Bashir Q, Chen J, Khouri IF, Kebriaei P, Anderlini P, Champlin R, Lima MD. Allogeneic Stem Cell Transplantation for CML in Second Chronic Phase After Blast Crisis in the Tyrosine Kinase Inhibitor Era. Blood 118(21):893-894, 2011. e-Pub 2011.
Farhan S, Lin H, Baladandayuthapani V, Shah N, Bashir Q, Hosing CM, Popat U, Parmar S, Dinh YT, Qureshi S, Rondon G, Giralt S, Champlin R, Qazilbash MH. Response Before Autologous Hematopoietic Stem Cell Transplantation Is An Important Predictor of Outcome in Multiple Myeloma. Blood 118(21):1760-1761, 2011. e-Pub 2011.
Lima MD, Ahmed S, Shpall EJ, Rondon G, Chen J, Woodworth GG, Chiattone A, Chu DT, Popat UR, Campos SR, Alousi AM, Hosing CM, Parmar S, Kebriaei P, Khouri IF, Cortes JE, Issa JJ, Champlin R. Sequential Therapy with Allogeneic Transplant Followed by Low-Dose Azacitidine for CML Patients That Failed Multiple Tyrosine Kinase Inhibitors. Blood 118(21):1342-1343, 2011. e-Pub 2011.
Saliba RM, Chiattone A, Majlis A, Chiattone VC, Rondon G, Sakashita AM, Hamerschlak N, Kutner JM, Shpall EJ, Anderlini P, Khouri I, Qazilbash MH, Popat U, Champlin R, Hosing CM, Lima MD. Predictors of Stem Cell Yield Via Apheresis in Patients Undergoing Stem Cell Mobilization. Blood 118(21):1733-1732, 2011. e-Pub 2011.
Parmar S, Rondon G, Thall PF, Bassett R, Lima MD, Hosing CM, Anderlini P, Kebriaei P, Khouri I, Ganesan P, Efebera YA, Champlin R, Giralt SA. Phase I/II Trial of Fludarabine in Combination with Intravenous Busulfan and Allogeneic Progenitor Cell Support for Patients with High Risk Hematologic Malignancies; Dose Matters in Reduced Intensity Regimens. Blood 118(21):848, 2011. e-Pub 2011.
Zhou Y, Jorgensen JL, Saliba RM, Wang SA, Rondon G, Ledesma C, Andersson BS, de Lima MJ, Shpall EJ, Popat U, Ciurea SO, Alousi AM, Qazilbash M, Hosing CM, Medeiros L, Champlin R, Kebriaei P. Pre-Transplant Minimal Residual Disease Detected by Multiparameter Flow Cytometric Analysis Predicts for Disease Relapse in Adult Patients with Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Stem Cell transplantation. Blood 118(21):1325, 2011. e-Pub 2011.
Shah N, Bashir Q, Parmar S, Dinh YT, Qureshi S, Rondon G, Popat UR, Nieto Y, Jones R, Champlin R, Qazilbash MH. Increased Bone Marrow Plasma Cell Infiltration Pre-Transplant Is Associated with Worse Outcomes in Patients Undergoing High Dose Chemotherapy and Autologous Stem Cell Transplantation for Multiple Myeloma. Blood 118(21):1768-1769, 2011. e-Pub 2011.
Kazmi S, Lu G, Shah N, Bashir Q, Parmar S, Orlowski RZ, Shah JJ, Hosing CM, Popat U, Dinh YT, Qureshi S, Rondon G, Giralt S, Champlin R, Qazilbash MH. A Comparative Study of the Outcome of High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation in Patients with High-Risk or Standard-Risk Myeloma Treated Concurrently. Blood 118(21):1778, 2011. e-Pub 2011.
Bayraktar UD, Lima MD, Rima SM, Maloy M, Castro-Malaspina H, Chen JJ, Rondon G, Chiattone A, Jakubowski AA, Boulad F, Kernan NA, O'Reilly RJ, Champlin R, Giralt SA, Andersson BS, Papadopoulos EB. Ex-Vivo T Cell-Depleted Versus Unmodified Allografts in Patients with Acute Myeloid Leukemia in First Complete Remission: A Comparison of Outcomes in Two Institutions. Blood 118(21):879-880, 2011. e-Pub 2011.
Nieto Y, Thall PF, Andersson BS, Popat UR, Anderlini P, Valdez BC, Shpall EJ, Qazilbash M, Alousi AM, Chancoco C, Hosing CM, Kebriaei P, Bashir Q, Shah N, Khouri I, Ciurea SO, McMullin B, Rondon G, Champlin R, Jones R. High-Dose Infusional Gemcitabine (Gem) Combined with Busulfan (Bu) and Melphalan (Mel) (GemBuMel) with Autologous Stem-Cell Transplant (ASCT) in Patients with Refractory Lymphoid Malignancies. Blood 118(21):1331-1332, 2011. e-Pub 2011.
Popat U, Andersson BS, Bassett R, Ciurea S, Rondon G, Alousi AM, Anderlini P, Hosing C, Jones R, Kebriaei P, Nieto Y, Khouri I, Shpall EJ, Verstovsek S, Qazilbash M, de Lima MJ, Champlin R. Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: PK Guided IV Busulfan Dose Intensity Results in Improved Event Free Survival. Blood 118(21):876, 2011. e-Pub 2011.
Bayraktar UD, Shpall EJ, Liu P, Ciurea SO, Lima MD, Rondon G, Price KJ, Champlin R, L Nates AJ. Hematopoietic Cell Transplantation – Specific Comorbidity Index As An Instrument to Predict Survival in Patients Admitted to Intensive Care Unit Early After Allogeneic Transplantation. Blood 118(21):71, 2011. e-Pub 2011.
Kota V, Saliba RM, Bayraktar UD, Beitinjaneh A, Chen JJ, Parmar S, Giralt SA, Rondon G, Ciurea SO, Kebriaei P, Qazilbash MH, Andersson BS, Champlin R, Lima MD. Chromosome 7 Abnormalities in Allogeneic Transplantation for AML and MDS. Blood 118(21):892-893, 2011. e-Pub 2011.
Andersson BS, de Lima MJ, Saliba RM, Shpall EJ, Popat U, Jones R, Nieto Y, Hosing CM, Kebriaei P, Alousi AM, Worth LL, Madden T, Gulbis A, Chen JJ, Rondon G, McAdams P, McMullin B, Andreeff M, Champlin R. Pharmacokinetic Dose Guidance of IV Busulfan with Fludarabine with Allogeneic Stem Cell Transplantation Improves Progression Free Survival in Patients with AML and MDS; Results of a Randomized Phase III Study. Blood 118(21):407-408, 2011. e-Pub 2011.
Qazilbash M, Thall PF, Liu P, Orlowski RZ, Bashir Q, Shah N, Kebriaei P, Parmar S, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Shah JJ, Lima MD, Champlin R, Giralt S. A Randomized Phase II Trial of Fludarabine/Melphalan 140 Vs Fludarabine/ Melphalan 100 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma. Blood 118(21):1754, 2011. e-Pub 2011.
Patel K, Orlowski RZ, Shah N, Bashir Q, Dinh YT, Rondon G, Giralt S, Champlin R, Qazilbash MH. Rima M Saliba, Alexandre Chiattone, Alejandro Majlis, Viviane C. Chiattone, Gabriela Rondon, Araci M. Sakashita, Nelson Hamerschlak, Jose Mauro Kutner, Elizabeth J Shpall, Paolo Anderlini, Issa Khouri, Muzaffar H Qazilbash, Uday Popat, Richard Champlin, Chitra M Hosing, and Marcos De Lima. Blood 118(21), 2011. e-Pub 2011.
Ahmed S, Dinh YT, Qureshi S, Rondon G, Bashir Q, Parmar S, Avery T, Orlowski RZ, Champlin R, Qazilbash M, Shah N. Survival Disparities Between African-American and Caucasian Patients Treated with Autologous Stem Cell Transplantation for Multiple Myeloma Are Eliminated in the Era of Novel Therapeutics. Blood 118(21):881-882, 2011. e-Pub 2011.
Patel K, Orlowski RZ, Shah N, Bashir Q, Dinh YT, Rondon G, Giralt S, Champlin R, Qazilbash MH. Durable Responses with Autologous Hematopoietic Stem Cell Transplantation in Patients with POEMS Syndrome. Blood 118(21), 2011. e-Pub 2011.
Ahmed S, Lin H, Baladandayuthapani V, Khan MA, Lu G, Rondon G, Qureshi S, Dinh YT, Bashir Q, Shah N, Parmar S, Hosing CM, Popat U, Giralt SA, Orlowski RZ, Shah JJ, Champlin R, Qazilbash MH. Impact of Non High-Risk Chromosomal Abnormalities on the Outcome of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Blood 118(21):156-157, 2011. e-Pub 2011.
Konopleva M, Zhihong Z, Wang R, Thall PF, McCormick G, Lu H, Chen JJ, Shpall EJ, Ciurea SO, Kebriaei P, Alousi AM, Popat U, Anderlini P, Nieto Y, Parmar S, McMullin B, Rondon G, Schober WD, Gulbis A, Cool R, Lin E, Andreeff M, Champlin R. A Phase I/II Trial of Plerixafor/G-CSF Combined with IV Bu/Flu Conditioning Regimen In AML/MDS Patients Undergoing Allogenic Stem Cell Transplantation. Blood 116(21):975, 2010. e-Pub 2010.
Parmar S, Khan M, Rondon G, Shah N, Bashir Q, Tung S, Shah JJ, Weber D, Orlowski RZ, Giralt S, Champlin RE, Qazilbash MH. Outcome of High Dose Melphalan with Autologous Hematopoietic Stem Cell Transplant In Myeloma Associated with AL Amyloidosis. Blood 116(21):995, 2010. e-Pub 2010.
De Lima M, Robinson S, McMannis J, Alousi AM, Saliba RM, Munsell M, Kebriaei P, Hosing C, Parmar S, Cooper L, Shah N, Kelly SS, Rondon G, Fernandez-Vina M, Maewall I, Bosque D, Bollard CM, Chen JJ, McNiece IK, Komanduri KV, Nieto Y, Jones R, Andersson BS, Popat U, Champlin RE, Simmons PJ, Shpall EJ. Mesenchymal Stem Cell (MSC) Based Cord Blood (CB) Expansion (Exp) Leads to Rapid Engraftment of Platelets and Neutrophils. Blood 116(21):164, 2010. e-Pub 2010.
Chiattone A, Saliba RM, Andersson BS, Giralt S, Sharma MR, Rondon G, Kebriaei P, Hosing C, Popat U, Parmar S, Alatrash G, Bashir Q, Chen JJ, Carrie Yuen H, Chiattone VC, Champlin RE, De Lima M. Treatment of AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Using Low-Dose Azacitidine (AZA). Blood 116(21):1413, 2010. e-Pub 2010.
Ciurea SO, Mulanovich VE, Jiang Y, Bassett R, Rondon G, McMannis J, de Lima M, Shpall EJ, Champlin RE. Lymphocyte Recovery Predicts Outcomes In Cord Blood and T-Cell Depleted Haploidentical Stem Cell Transplantation. Blood 116(21):956, 2010. e-Pub 2010.
Bashir Q, Wei W, Chiattone A, Rondon G, Parmar S, Shah N, Booc EH, Yvonne D, Sofia Q, Shah JJ, Orlowski RZ, Weber D, Champlin R, Giralt S, Qazilbash MH. Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma. Blood 116(21), 2010. e-Pub 2010.
Stefan Ciurea SO, Aung F, de Lima M, Thall PF, Rondon G, Kebriaei P, Alousi A, Shpall EJ, Hosing C, Khouri IF, Champlin RE, Fernandez-Vina M. Anti-HLA Antibodies and Graft Rejection In Hematopoietic Stem Cell Transplantation. Blood 116(21):229-230, 2010. e-Pub 2010.
Ciurea SO, Saliba RM, Rondon G, Patah PA, Aung F, Andersson BS, Kebriaei P, Popat U, Fernandez-Vina M, Champlin RE, de Lima M. Superior Outcomes with Matched Unrelated Donors Compared with One Human Leukocyte Antigen Mismatched Related Donors In Allogeneic Hematopoietic Stem Cell Transplantation. Blood 116(21):400, 2010. e-Pub 2010.
Bashir Q, Wei W, Chiattone A, Rondon G, Parmar S, Shah N, Booc EH, Yvonne D, Sofia Q, Shah JJ, Orlowski RZ, Weber D, Champlin R, Giralt S, Qazilbash MH. Autologous Hematopoietic Cell Transplantation In Multiple Myeloma Patients Age 70 Years and Older. Blood 116(21), 2010. e-Pub 2010.
Parmar S, Khan M, Rondon G, Shah N, Bashir Q, Tung S, Shah JJ, Weber D, Orlowski RZ, Giralt S, Champlin RE, Qazilbash MH. High Dose Melphalan with Autologous Stem Cell Transplantation Overcomes Poor Prognosis of Primary Amyloidosis. Blood 116(21):579-580, 2010. e-Pub 2010.
Ciurea SO, Saliba RM, Rondon G, Patah PA, Rodrigues M, Aung FM, Andersson BS, Parmar S, Champlin RE, de Lima M, Fernandez-Vina M. Outcomes of Patients Treated with Matched and Mismatched Unrelated Donors Using High-Resolution HLA Typing at 12 Loci. Blood 116(21):1454-1455, 2010. e-Pub 2010.
Borthakur G, Beitinjaneh A, Lin E, Cortes JE, Luthra R, Ravandi F, Pierce SA, Patel AH, Rondon G, Giralt S, Champlin R, Kantarjian H, de Lima M. Impact of FLT3-ITD Allelic Ratio In Treatment of Acute Myelogenous Leukemia Including Allogeneic Stem Cell Transplant. Blood 116(21):721, 2010. e-Pub 2010.
Champlin R, Lee DA, Fernandez-Vina M, Rondon G, McAdams P, Julianne C, Qazilbash MH, Kebriaei P, Parmar S, Shpall EJ, Popat U, Alousi A, Ciurea SO, Cooper L, Peter T, McMannis J. Alloreactive Nk Cells to Augment Antileukemia Cytotoxicity with Allogeneic Stem Cell Transplantation for Aml/Mds: A Phase I Study. Blood 116(21):217, 2010. e-Pub 2010.
Alousi AM, Andersson BS, Saliba RM, Botnick W, Rondon G, Shpall EJ, de Lima M, Popat U, Hosing C, Kebriaei P, Khouri I, Qazilbash MH, Anderlini P, Nieto Y, Ciurea S, Jones R, Champlin R. Reduced Intensity Conditioning Combined with Post-Transplant Cyclophosphamide for Graft Vs. Host Disease Prophylaxis In Older-Aged or Medically Frail Patients with Advanced Hematological Malignancies. Blood 116(21):967-968, 2010. e-Pub 2010.
Tang X, De Lima M, Wei W, Chiattone A, Thall PF, Jeffrey M, Rondon G, Chen JJ, Shpall EJ, Jones R, Nieto Y, Alousi AM, Champlin RE, Andersson BS. Early Mixed Chimerism After Allogeneic Stem Cell Transplantation with the Reduced-Toxicity IV Busulfan-Fludarabine (BuFlu) Regimen Does Not Independently Affect Long-Term Prognosis for Patients with AML/MDS. Blood 116(21):1414, 2010. e-Pub 2010.
Lima MD, McMannis J, Komanduri K, Worth L, Karandish S, Jones R, Giralt S, Cooper L, Padua L, Patah P, Petropoulos D, Thall P, Zhang W, Qiao W, Robinson S, Qureshi S, Khouri I, Hosing C, Alousi A, Rondon G, Andersson BS, Champlin R, Shpall EJ. Randomized Study of Double Cord Blood Transplantation (CBT) with Versus without Ex-Vivo Expansion (EXP). Blood 110(11), 2007. e-Pub 2007.
Ciurea SO, Qureshi S, Rondon G, Pesoa S, Cano P, McMannis J, Giralt S, Lima MD, Fernandez-Vina M, Champlin RE, Gajewski J. Sustained Engraftment Using Fludarabine, Melphalan and Thiotepa Conditioning for Haploidentical Stem Cell Transplantation. Blood 110(11), 2007. e-Pub 2007.
Champlin RE, Giralt S, Shpall E, Kebriaei P, Anderlini P, Qazilbash M, McMannis J, McCormick G, Fisher T, Lima MD, Rondon G. Nonmyeloablative Allogeneic Transplantation in the Imatinib Era: Three Chances To Achieve Molecular Remission in CML. Blood 110(11), 2007. e-Pub 2007.
Patah P, Saliba R, Fernandez-Vina M, Cano P, Pesoa S, Rondon G, Andersson B, Giralt S, Kebriaei P, Hosing C, Anderlini P, Couriel D, Alousi A, Padua L, Ramos C, Champlin R, Lima MD. A Comparison of 1 Antigen-Mismatched Related and Matched Unrelated Transplants. Blood 110(11), 2007. e-Pub 2007.
Rivera ZP, Gulbis AM, de Lima M, Rondon G. Predictive factors for engraftment in bone marrow transplant recipients. Biology of Blood and Marrow Transplantation 13, 2007. e-Pub 2007.
Popat UR, Rondon G, Alousi AM, Anderlini P, Andersson BS, de Lima MJ, Giralt SA, Hosing CM, Kebriaei P, Jones R, Nieto Y, Shpall EJ, Verstovesek S, Qazilbash MH, Champlin R. Myelofibrosis and Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RISCT). Blood 110(11), 2007. e-Pub 2007.
Tam CS, Ledesma C, Korbling M, Fayad LE, Wang M, Alousi A, Hosing C, Kebriaei P, Rondon G, Giralt SA, Anderlini P, Popat U, Couriel D, Pro B, Samuels B, Hagemeister F, Champlin RE, Khouri IF. Non-Myeloablative Allogeneic Stem Cell Transplantation (NMT) Overcomes the Adverse Effects of Treatment Resistance and High Beta-2-Microglobulin in Patients with Mantle Cell Lymphoma (MCL): An Analysis of 123 Transplantations at the MD Anderson Cancer Center. Blood 110(11), 2007. e-Pub 2007.
Patah P, Fernandez-Vina M, Stastny P, Liu P, Cano P, Pesoa S, Shpall EJ, Giralt S, Khouri I, Anderlini P, Alousi A, Padua L, Ramos C, Rondon G, Nieto Y, Champlin R, Lima MD. Mismatches in Low Expression HLA Class II Loci and MIC-A in Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT). Blood 110(11), 2007. e-Pub 2007.
Saliba RM, Komanduri K, Giralt S, de Souza J, Patah PA, Oran B, Rondon G, Couriel DP, Champlin R, de Lima M. Correlates and outcome of absolute lymphocyte count (ALC) on day 30 post allogeneic stem cell transplantation (SCT) for treatment of AML. Biology of Blood and Marrow Transplantation 13, 2007. e-Pub 2007.
Blackburn RK, Giralt SA, Saliba RM, Rondon G, Fenwick JN. Acute hypertensive crisis during infusion of hematopoietic progenitor cell from matched unrelated donors: Identification of predictive factors and optimal treatment. Biology of Blood and Marrow Transplantation 12, 2006. e-Pub 2006.
Lima MD, Patah PA, Saliba R, Couriel D, Chan K, Worth L, Giralt S, Kebriae P, Khouri I, Cooper L, Fernandez-Vina M, Cano P, Petropoulos D, McMannis J, Hosing C, Rondon G, Komanduri KV, Champlin RE, J Shpall AE. Donor-Recipient Host-Versus-Graft (HVG) HLA Mismatches and Outcome of Cord Blood Transplants (CBT). Blood 108, 2006. e-Pub 2006.
de Souza JA, Saliba R, Patah PA, Rondon G, Qazilbash MH, Hosing C, Popat U, Champlin RE, Lima MD. Renal Function Impairment and Outcomes of Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation. Blood 108, 2006. e-Pub 2006.
Patah PA, Parmar S, Lima MD, Sadeghi T, Karandish S, McMannis J, Rondon G, Tarrand J, Champlin R, J Shpall AE. Infusion of Microbially Contaminated Hematopoietic Cell Products Has No Adverse Effect on Clinical Outcome. Blood 108, 2006. e-Pub 2006.
Lima MD, Parmar S, Liu P, Patah PA, Cano P, Shpall EJ, Hosing C, Couriel D, Anderlini P, Giralt S, Andersson BS, Kebriaei P, Rondon G, Champlin R, Fernandez-Vina M. HLA-DP Mismatches Increase the Risk of Acute GVHD after Unrelated Donor Hematopoietic Transplantation (UDT). Blood 108, 2006. e-Pub 2006.
Patah PA, Gurkan E, Saliba R, Lima MD, Rondon G, Ramos CA, Couriel D, de Souza JA, Champlin R, Lichtiger B. "Prophylactic" Platelet (PLT) Transfusions in the Setting of Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT): Similar Clinical Efficacy of Single Donor (SDP) and Random Donor Pooled (RDP) Platelet Products. Blood 108, 2006. e-Pub 2006.
Ueno NT, Rondon G, Williams P, Champlin RE, Murray JL, Cristofanilli M, Royce M, Walter RB, Theriault RL, Hortobagyi GN, Valero V. Trastuzumab plus GM-CSF for patients with trastuzumab-resistant, HER2-overexpressing metastatic breast cancer: Pilot study. Journal of Clinical Oncology 12, 2005. e-Pub 2005.
Khouri IF, Tarrand JJ, Okoroji G, Saliba RM, Hosing CM, Couriel DR, Kebriaei P, Griffith D, Rondon G, Ippoliti C, Champlin RE. Campath-IH Combined with Fludarabine/Cyclophophamide/Rituximab (FCR) as Conditioning for Unrelated Non-Myeloablative Hematopoietic Transplantation (NMT) for Non-Hodgkin’s Lymphoma (NHL): Low Mortality Rate and Lower Than Expected Incidence of Cytomegalovirus (CMV) Reactivation. Blood 106, 2005. e-Pub 2005.
Hamaoka T, Madewell JE, Costelloe CM, Islam R, Rondon G. Accurate response assessment of breast cancer bone metastasis using computed tomography and new response criteria. Journal of Clinical Oncology 23, 2005. e-Pub 2005.
Booser DJ, Ueno NT, Rondon G, Williams PA, Wendt R, Hortobagyi GN, Podoloff DA, Champlin RE. Complete response of bone-only metastatic breast cancer to sketetal: Targeted radiotherapy with 166 HOLMIUM-DOTMP. Journal of Clinical Oncology 23, 2005. e-Pub 2005.
Champlin RE, Booser D, Rondon G, Williams PA, Wendt R, Hortobagyi G. Targeted radiotherapy to the skeleton using 166Ho-DOTMP with autologous stem cell transplantation for patients with bone-only metastatic breast cancer. Biology of Blood and Marrow Transplantation 11:84-85, 2005. e-Pub 2005.
Rondon G, Khouri I, Giralt S, Chan K, McMannis J, Champlin R, Shpall E. Long-term follow up of patients who experienced graft failure post allogeneic progenitor cell transplantation. Biology of Blood and Marrow Transplantation 11:31-32, 2005. e-Pub 2005.
Jabbour EJ, Shahjahan M, Rondon G, Anderlini P, Giralt S, Couriel DR, Champlin RE, F Khouri AI. Treatment of Graft Failure with Fludarabine (Flu), Antithymocyte Globulin (ATG) and Second Allogeneic Stem Cell Transplantation (SCT). Blood 106, 2005. e-Pub 2005.
Cheng YCC, Rondon G, Couriel DR, Lima MJ, Hosing C, Khouri IF, Giralt SA, Gajewski JL, Champlin RE. Interleukin-2 (IL-2) with highdose chemotherapy (HDC) and autologous hematopoietic stem-cell transplantation (AHST) for poor-risk metastatic breast cancer (MBC). Journal of Clinical Oncology 22, 2004. e-Pub 2004.
Gajewski JL, Saliba R, Rondon G, Ueno NT, Donato ML, Anderlini P, Korbling M, McMannis JD, Giralt SA, Khouri IF, Mehra R, E Champlin AR. High Doses of CD34+ Cells Chemomobilized with G-CSF PBPC Collection Had Greater CD34(+) Cells Collected Than G-CSF Alone and Trended toward Reduced Progression Rate after Autologous PBPC Transplantation for Breast Cancer in a Phase III Trial. Blood 104, 2004. e-Pub 2004.
Cheng YC, Saliba RM, Rondon G, Giralt SA, Lu KH, Bodurka DC, Gershenson DM, Champlin RE, Ueno NT. Reduced-intensity conditioning (RIC) regimens result in low prevalence of premature ovarian failure (POF) in women underwent hematopoietic stem-cell transplantation (HST). Biology of Blood and Marrow Transplantation 10:25-26, 2004. e-Pub 2004.
Lima MD, Shahjahan M, Alamo J, Williams P, Wolff BV, Couriel D, Khouri I, Rondon G, Wheeler B, Estey E, Ueno N, Kebriaei P, Champlin R, Giralt AS. Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Patients Aged 65 Years or Older with AML and MDS. Blood 104:2301, 2004. e-Pub 2004.

Book Chapters

Rondon, G. Graft Failure After Hematopoietic Cell Transplantation. Elsevier, 443-451, 2023.

Letters to the Editor

Subramanian, NG, Guffey, D, Avery, J, Garcia, D, Basom, R, Lee, SJ, Klein, K, Kebriaei, P, Rondon, G, Shpall, E, Jin, S, Young, E, Rojas Hernandez, CM, Li, A. Clinical Factors Associated With Catheter-Related VTE in Patients Undergoing Hematopoietic Cell Transplantation. American journal of hematology 100: 1463-1466, 2025.

Less

CV information above last modified March 09, 2026

Gabriela Rondon, M.D.

About Dr. Gabriela Rondon

Present Title & Affiliation

Primary Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Intramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

National Presentations

International Presentations

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Review Articles

Other Articles

Abstracts

Book Chapters

Letters to the Editor

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Gabriela Rondon, M.D.

About Dr. Gabriela Rondon

Present Title & Affiliation

Primary Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Intramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

National Presentations

International Presentations

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Review Articles

Other Articles

Abstracts

Book Chapters

Letters to the Editor

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson